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Eukaryotic translation initiation factor 4E (eIF4E) is considered as the corner stone in the cap-dependent
translation initiation machinery. Its role is to recruit mRNA to the ribosome through recognition of the 50-
terminal mRNA cap structure (m7GpppN, where G is guanosine, N is any nucleotide). eIF4E is implicated
in cell transformation, tumourigenesis, and angiogenesis by facilitating translation of oncogenic mRNAs;
it is thus regarded as an attractive anticancer drug target. We have used two approaches to design cap-
binding inhibitors of eIF4E by modifying the N7-substituent of m7GMP and replacing the phosphate
group with isosteres such as squaramides, sulfonamides, and tetrazoles, as well as by structure-based
virtual screening aimed at identifying non-nucleotide cap-binding antagonists. Phosphomimetic nucle-
otide derivatives and highly ranking virtual hits were evaluated in a series of in vitro and cell-based
assays to identify the ﬁrst non-nucleotide eIF4E cap-binding inhibitor with activities in cell-based as-
says, N-[(5,6-dihydro-6-oxo-1,3-dioxolo[4,5-g]quinolin-7-yl)methyl]-N0-(2-methyl-propyl)-N-(phenyl-
methyl)thiourea (14), including down-regulation of oncogenic proteins and suppression of RNA incor-
poration into polysomes. Although we did not observe cellular activity with any of our modiﬁed m7GMP
phosphate isostere compounds, we obtained X-ray crystallography structures of three such compounds
in complex with eIF4E, 50-deoxy-50-(1,2-dioxo-3-hydroxycyclobut-3-en-4-yl)amino-N7-methyl-guano-
sine (4a), N7-3-chlorobenzyl-50-deoxy-50-(1,2-dioxo-3-hydroxy-cyclobut-3-en-4-yl)amino-guanosine
(4f), and N7-benzyl-50-deoxy-50-(triﬂuoromethyl-sulfamoyl)guanosine (7a). Collectively, the data we
present on structure-based design of eIF4E cap-binding inhibitors should facilitate the optimisation of
such compounds as potential anticancer agents.
© 2016 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
In eukaryotes, most mRNAs are translated using a cap-
dependent mechanism, which consists of three stages: initiation,n factor; 4E-BP, eF4E-binding
thyl guanosine; RRL, rabbit
.M. Fischer).
r Masson SAS. This is an open acceelongation, and termination. The initiation step requires a number
of eukaryotic translation initiation factors (eIFs) [1]. Initially, the
40S ribosomal subunit associates with Met-tRNAi and a group of
initiation factors, including eIF1, eIF1A, eIF2, eIF3, and eIF5 to form
the 43S pre-initiation complex [2]. This complex is then recruited to
the 50-end of capped mRNA by another complex of factors (known
as eIF4F) consisting of eIF4E, eIF4G, and eIF4A. eIF4E is an indis-
pensable element for cap-dependent translation initiation and
plays a major role in recognition of the mRNA cap structure
(m7GpppN, where N is any nucleotide). It binds to eIF4G, which
serves as a scaffolding protein to gather eIF4A (ATP-dependent RNAss article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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complex [3,4]. This complex then scans the mRNA for an initiation
codon and, once this is located, the 60S ribosomal subunit joins to
form the elongation-competent fully functional 80S.
Under typical circumstances, eIF4E is the least abundant of the
cellular translation initiation components [5] and it represents the
rate-limiting element for the initiation process [6,7]. Under resting
conditions, eIF4E is kept in an inactive form bound to 4E-binding
proteins (4E-BPs); once the latter have been phosphorylated
through the PI3K-AKT-mTOR signalling pathway, eIF4E is released
and can associate with eIF4G to launch translation.
eIF4E is overexpressed in numerous human tumours, and it
contributes to transformation, tumourigenesis, and progression of
cancers [8,9]. eIF4E overexpression facilitates translation of weak
and highly structured mRNAs that typically encode proteins
involved in cancer pathology, such as proto-oncoproteins (e.g.
cyclin D1, ornithine decarboxylase), angiogenesis factors (e.g. FGF-
2, VEGF), and factors related to tumour invasiveness, such as
MMP-9 [10], due to the ability of eIF4E to stimulate eIF4A [11]. For
these reasons, eIF4E represents an attractive cancer drug target
[12]. Moreover, a recent study suggests that targeting eIF4E for
cancer treatment has minimal effects on growth of eand protein
synthesis ine healthy cells [13].
Strategies to design eIF4EemRNA cap-binding antagonists have
been based on nucleoside (purine N7-substitutions) [14e17] and
nucleotide (altered phosphate groups) [17e19] modiﬁcations of 7-
methylguanosine (m7G) nucleotides (Fig. 1) [12], including recent
work affording for the ﬁrst time m7G monophosphate (m7GMP)
nucleotide mimetic compounds with high afﬁnity for eIF4E [20].
However, to date no cell-permeable small-molecule eIF4E cap-
binding antagonists have been reported. As with antiviral agents
derived from nucleotides, prodrugs that mask the ionic nature of
phosphate groups, such as phosphate esters of phosphoramidates,
may offer an avenue for the design of cell-permeable eIF4E in-
hibitors, but this strategy has not progressed very far as yet [21].
Here we report on new methods to design cap antagonists and
we show a group of nucleotide mimetic compounds with phos-
phate group isosteres and various purine N7-substituents. The
biological activities of these compounds were assessed using aFig. 1. (a) mRNA cap recognition (represented by m7GTP shown as yellow CPK sticks) and b
cyan cartoon) occurs on opposite faces of eIF4E (green cartoon). Apart from direct cap-bin
sticks) and inhibitors derived from eIF4G and 4E-BPs [23] are being developed. Whereas m
system and eIF4E residues W56, W102, and E103 (cationep interaction and H-bonds), as wel
N7-substituents other than methyl, such as 4-ﬂuorobenzyl [24] (green) or (4-chlorophenoxy
(surface representations) behind the W56eW102 stack. Figure constructed from PDB entr
Figures were prepared using MacPyMOL (The PyMOL Molecular Graphics System, Version 1.2
the reader is referred to the web version of this article.)range of techniques and the eIF4E-binding modes of three com-
pounds were determined experimentally using X-ray crystallog-
raphy. However, despite phosphate group modiﬁcations, these
nucleotide mimetics still exhibit poor cellular bioactivity. There-
fore, a computer-aided drug designmethodwas exploited to design
a set of non-nucleotide compounds to provide the ﬁrst small-
molecule eIF4E inhibitor possessing cellular activity consistent
with blocking of eIF4E-mediated initiation of translation.
2. Results and discussion
2.1. Design and synthesis of nucleotide monophosphate mimetic
eIF4E inhibitors
One of the main challenges in the design of inhibitors of eIF4E
cap binding has been to achieve membrane permeability and thus
cellular bioavailability [20]. This is due to the fact that the afﬁnity of
eIF4E for the RNAm7GpppN cap structure derives in large part from
polar interactions between the ligand triphosphate group and the
receptor protein (Fig. 1a) [15,25]. In order to address the perme-
ability problem, as well as the intrinsic hydrolytic and enzymatic
lability of nucleotides, we aimed to design nucleoside mono-
phosphate mimetics [25,26]. Several phosphate group re-
placements were investigated, such as squaramides, sulfonamides,
and tetrazoles. Since e.g. m7GMP has much lower afﬁnity for eIF4E
than m7GTP [25], we expected to compensate the loss in afﬁnity
with nucleoside monophosphate mimetics through optimal purine
N7-substituent modiﬁcations, based on previous studies demon-
strating that replacing the N7-methyl group with bulkier groups
contributed signiﬁcantly to ligand afﬁnity (Fig. 1b) [27,28].
Squaric acid possesses similar charge distribution, polarity, and
acidic properties as phosphoric acid, hence the squaramide group
could represent an isostere for the phosphate group [29,30].
Similarly, sulfonamide derivatives have been reported as phosphate
mimics in the design of tyrosine phosphatase inhibitors [31]. The
third candidate we considered for phosphate group replacement
was a tetrazole [32], as this systemmimics the acidic features of the
phosphate group, provided the proton attached to one of the tet-
razole ring nitrogens is not replaced [33].inding of eIF4G or 4E-BPs (represented by a peptide derived from 4E-BP1 shown as a
ding antagonists, allosteric inhibitors (binding pose of 4-EGI1 [22] shown as magenta
7GTP-binding is dominated by polar interactions between the cationic N-methylpurine
l as the phosphate groups with residues R157, K159, and K162, (b) GMP derivatives with
)ethyl [20] (cyan), also make hydrophobic contacts with two concave lipophilic pockets
ies 2V8W, 2V8Y, 4DT6, and 4TPW. 3D-Structure illustrations in this and subsequent
, Schr€odinger, LLC). (For interpretation of the references to colour in this ﬁgure legend,
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tide cap mimetics was the protected guanosine derivative 1e
(Scheme 1) [34], which was prepared by ﬁrst blocking the 20,30-
vicinal glycol of guanosine as the acetonide 1a [35], followed by
dimethoxytritylation of the exocyclic amine group (1b) [36], and
transformation of the 50-hydroxyl group to the amine via successive
conversion to the iodide 1c and azide 1d, and reduction of the latter
[37]. The amine 1e was condensed either with dimethyl squarate
[29] to afford the squaramide derivative 2 or with polar sulfonyl
chlorides to furnish the sulfonamide derivatives 5. These in-
termediates were N7-alkylated using a range of alkyl or aryl bro-
mides [14] to provide the methyl squaramides 3 and sulfonamides
6. The methyl squaramide groups of the former were ﬁrst deme-
thylated with sodium iodide in acetone [38], followed by treatment
with aqueous formic acid to afford the squaramides 4. The aceto-
nide group of precursors 6 was removed similarly with formic acid
to provide the sulfonamides 7 [39]. The tetrazole derivatives 11
were also elaborated from 1e, by Boc-protection of the 50-amino
group (8), followed by N7-alkylation (9), global deprotection (10),
and acylation of the 50-amino group with 1H-tetrazole-5-aceticScheme 1. Preparation of nucleotide mimetics 4ae4i, 7ae7c, and 11ae11ba. a Conditions:
pyridine, NH4OH; (v) dimethyl squarate, iPr2NEt, MeOH; (vi) R-X, DMF; (vii) NaI, Me2CO, D, th
Et3N, CH2Cl2, 24 h; (xi) 5-tetrazole acetic acid, DIC, Et3N, DMF.acid.
2.2. Design of non-nucleotide eIF4E inhibitors
As an alternative to nucleoside monophosphate mimetics we
considered structure-based design of eIF4E cap-binding antago-
nists. For this purposewe dockedmulti-conformer libraries of lead-
like molecules from the ZINC [40] database to a model of the
Bn7GMP-binding site of eIF4E derived from a complex crystal
structure we reported earlier (PDB entry 2V8Y) [15] using shape-
based fast rigid exhaustive docking (FRED) [41,42]. We applied a
combination of scoring functions, including functions based on
Poisson-Boltzmann electrostatic potentials, in order to ensure that
interactions of virtual hits mimicking the cationep interaction
[43,44] of the N7-methylguanine system in the mRNA cap with the
eIF4E W56eW102 indole side chains (Fig. 1a) would be rewarded.
The virtual screening protocol was validated by docking and
scoring a set of 500 randomly-chosen diverse decoy molecules
from the ZINC database spiked with a set of N7-alkylated cap-
derived nucleotides known to bind eIF4E, as well their non-(i) DMTr-Cl, Me3SiCl; (ii) (PhO)3PþMeI, THF, 78 C; (iii) NaN3, DMF, 85 C; (iv) Ph3P,
en 80% aq HCOOH, 24 h; (viii) RSO2Cl, Et3N, CH2Cl2; (ix) 80% aq HCOOH,12 h; (x) Boc2O,
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[25]. This analysis revealed that the N7-alkylated cap-derived nu-
cleotides populated the top 12% of the hit list from the combined
scoring protocol. Based on this result we proceeded to screen the
entire lead-like subset of the ZINC database. We acquired several
hundred of the top-ranking virtual hits and submitted these to the
mass spectrometry-based assay described earlier [45], as well as
the ﬂuorescence polarisation (FP) assay described below. The
chemical structure and predicted properties of the most highly
scored virtual hits are shown in Table 1.
2.3. Biological activity of nucleotide monophosphate mimetic and
non-nucleotide eIF4E inhibitors
In order to assess our m7GMP-derived compounds and virtual
screening hits as mRNA cap-binding antagonists, we developed an
FP assay (Fig. 2) based on displacement of a ﬂuorescently labelled
m7GDP derivative from eIF4E by cap-binding inhibitors. Assay
optimisation showed that a tracer concentration of 10 nM and an
eIF4E concentration of 90 nM was optimal. All test compounds
were screened initially at 100 mM and actives were titrated to
calculate Kd values, summarised in Table 2.
As expected, m7GTP had almost 10-fold higher afﬁnity for eIF4ETable 1
Chemical structures and predicted properties of virtual hits 12e16 from structure-based
Cmpd Source CASa Mr Predicted proper
logP logD
12a Asinex
BAS04026402
557064-00-3 356.4 0.9 1.1
12b Asinex
BAS02054521
338425-77-7 325.4 1.2 1.8
12c Asinex
BAS02563297
333412-47-8 325.4 1.2 1.8
13 Asinex
ASN03777735
459445-48-8 420.6 4.3 4.3
14 Asinex
ASN03775814
461002-66-4 423.5 4.0 4.0
15 ChemBridge
6373744
426248-94-4 336.8 3.8 3.8
16 ChemBridge
8893829
899375-48-5 349.8 2.3 2.3
a Chemical Abstracts Registry Number.
b Using ChemAxon InstantJChem version 15.6.8.0.
c Predicted logD at pH ¼ 7.4.
d Topological polar surface area.
e Number of non-terminal rotatable bonds.
f Log10 of predicted molar intrinsic aqueous solubility.
g Criteria: nRot < 10 and TPSA < 140 Å2 [46].
h Criteria: Mr  450, 4  logD7.4  4, number of rings  4, nRot  10, number of H-in our FP assay than m7GMP. Although the majority of the squar-
amide (4), sulfonamide (7), and tetrazole (11) phosphate-mimetic
analogues inhibited tracer binding in the FP assay at the pre-
screen concentration of 100 mM to some extent, only the sulfon-
amides 7a and 7b showed levels of inhibition that permitted
construction of a sufﬁciently wide doseeresponse titration for ac-
curate Kd determination. Of the squaramides, all derivatives except
4a, 4c, and 4f showed insigniﬁcant inhibition (<10%) in the pre-
screen. Surprisingly, in the context of the squaramide phospho-
mimetic group, the expected enhancement of afﬁnity upon
replacing the N7-methyl group (4a) with a benzyl group (4b) was
not observed. Furthermore, substitution of the phenyl group with
small and electronically neutral groups (3-Me, 4c; 3-Cl, 4f) retained
the modest activity of 4a and 4b, whereas introduction of larger
and more polar substituents reduced or abolished activity. The
triﬂuoromethyl- and the para-carboxyphenyl sulfonamides 7a and
7b were the only nucleoside monophosphate mimetic compounds
for which Kd values could be obtained, and these are signiﬁcantly
higher than that of m7GMP. The tetrazole derivatives 11 had very
modest activity. Here the N7-benzyl derivative 11b was somewhat
more active than the N7-methyl compound 11a.
Amongst the virtual screening hits, a cluster of 4,5-bisaryl-2-
carboxymethylthio-1,2,3-triazoles 12aec was identiﬁed but thesedesign.
tiesb
c TPSAd (Å2) nRote logSif Drug-likeg Lead-likeh
90 7 4.7 yes yes
87 5 4.9 yes yes
87 5 4.9 yes yes
76 4 5.9 yes no
63 6 7.1 yes no
66 3 6.9 yes yes
62 1 4.5 yes yes
bond donors  5, number of H-bond acceptors  8 [47].
Fig. 2. (a) Recombinant eIF4E or bovine serum albumin (BSA) was titrated against the FP probe ATTO-465-labelled 20/30-O-(2-aminoethylcarbamoyl)-7-methyl-guanosine-50-
diphosphate (EDA-m7GDP-ATTO-465, structure shown inset; 10 nM) and a Kd value with respect to eIF4E binding was calculated. (b) The FP assay is speciﬁc for the unique structural
feature of the mRNA cap and can distinguish between m7GTP and GTP (eIF4E concentration: 90 nM).
Table 2
Summary of biological activities of compounds 4e16.a
Cmpd FP assay RNA cross-linking assay Reticulocyte lysate assay 35S-Met incorporation assay
Inhibition (%)b Kd (mM) Inhibition (%)b IC50 (mM) IC50 (mM) IC50 (HeLa) IC50 (MCF-7)
m7GTP 97.3 ± 2.4c 0.37 ± 0.03 92.8 ± 1.6c 0.72 ± 0.14 8.6 ± 1.1 Inactive Inactive
m7GMP 86.3 ± 5.0 3.9 ± 0.5 97.5 ± 0.8 1.7 ± 0.1 46.9 ± 3.4 Inactive Inactive
4a 14.4 ± 3.2 n.d.d Inactive n.d. n.d. n.d. n.d.
4b 9.1 ± 5.5 n.d. Inactive n.d. n.d. n.d. n.d.
4c 15.2 ± 4.7 n.d. Inactive n.d. n.d. n.d. n.d.
4d 2.0 ± 6.3 n.d. Inactive n.d. n.d. n.d. n.d.
4e Inactive n.d. Inactive n.d. n.d. n.d. n.d.
4f 13.2 ± 4.2 n.d. Inactive n.d. n.d. n.d. n.d.
4g 3.9 ± 5.2 n.d. Inactive n.d. n.d. n.d. n.d.
4h 1.8 ± 7.7 n.d. 6.5 ± 7.1 n.d. n.d. n.d. n.d.
4i Inactive n.d. Inactive n.d. n.d. n.d. n.d.
7a 89.0 ± 1.7 56.5 ± 6.9 42.9 ± 4.8 12.6 ± 0.5 65.9 ± 13.6 Inactive Inactive
7b 49.4 ± 6.3 133 ± 28 48.6 ± 1.3 18.7 ± 5.0 165 ± 32 Inactive Inactive
7c Inactive n.d. 22.2 ± 1.8 n.d. n.d. n.d. n.d.
11a 9.7 ± 2.9 n.d. 25.8 ± 2.9 n.d. n.d. n.d. n.d.
11b 30.2 ± 2.8 n.d. 15.3 ± 4.8 n.d. n.d. n.d. n.d.
12a 13.6 ± 2.2 n.d. 10.2 ± 3.3 n.d. n.d. n.d. n.d.
12b 25.8 ± 5.9 n.d. Inactive n.d. n.d. n.d. n.d.
12c 8.5 ± 2.8 n.d. Inactive n.d. n.d. n.d. n.d.
13 Inactive n.d. Inactive n.d. n.d. n.d. n.d.
14 68.1 ± 0.8 57.8 ± 13.5 47.5 ± 6.7 38.6 ± 10.6 65.1 ± 12.5 35.2 ± 4.0 37.7 ± 10.4
15 Inactive n.d. 3.5 ± 3.2 n.d. n.d. n.d. n.d.
16 Inactive n.d. 33.8 ± 8.1 n.d. n.d. n.d. n.d.
a All experiments were carried out on three independent occasions.
b At 100 mM concentration unless otherwise indicated.
c At 10 mM concentration.
d Not determined.
F. Soukarieh et al. / European Journal of Medicinal Chemistry 124 (2016) 200e217204showed low activity in the FP prescreen and Kd values could not be
determined. Of the somewhat structurally related quinolinones 13
and 14, the former was essentially without activity in the FP assay,
whereas the latter was clearly active, at a level similar to the best of
the nucleotide derivatives (7b). The thiazolone 15 and the pyr-
idothiazolopyrimidine 16 showed no activity in the FP assay.
Further to conﬁrm inhibition of eIF4E cap binding, a radiometric
competition binding assay was developed based on an in vitro UV
cross-linking technique widely used to study proteineRNA in-
teractions [48]. In this assay, a radiolabelled and capped RNA was
incubated with eIF4E in the presence or absence of putative in-
hibitors 4e16. The RNAeeIF4E complexes formed were cross-
linked, separated by SDS-PAGE, and quantitated by autoradiog-
raphy. The assay was validated with positive controls (m7GMP andm7GTP), test compounds were pre-screened at 100 mM (Table 2),
and for sufﬁciently active compounds half-maximal inhibitory
concentration (IC50) values were determined (Fig. 3).
As expected, m7GMP andm7GTP displayed similar activity levels
in the UV cross-linking assay as in the FP assays. The squaramides 4
were inactive with the exception of the derivative 4h. All three
sulfonamides 7 showed activity in the UV cross-linking assay and
for 7a and 7b IC50 values could be determine (Fig. 3). For the in-
hibitors from the virtual screen (11e16), the UV cross-linking assay
results mirrored those from the FP assay but an IC50 value could
only be determined for quinolinone 14.
For the nucleoside monophosphate mimetic compounds, which
we expected to be devoid of cellular bioactivity, we also sought to
obtain a functional read-out of eIF4E inhibition. For this purposewe
Fig. 3. Doseeresponse curves for m7GMP, m7GTP, as well as compounds 7a, 7b, and 14
in the radiolabelled and capped RNA (5 nM) e eIF4E (1.5 mM) UV cross-linking assay.
Inhibitor concentrations are plotted against autoradiography band intensities
following separation of the cross-linked RNAeeIF4E complexes.
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observe the translational consequences of eIF4E inhibition [49].
Test compounds m7GMP, m7GTP, as well as the sulfonamides 7a
and 7b were incubated in the RRL system, which was primed with
luciferase RNA, and expression of luciferase was then quantitated.
From the results (Table 2) it can be observed that all four test
compounds inhibited luciferase synthesis. For m7GMP and m7GTP
the IC50 values in the RRL assaywere signiﬁcantly higher than those
determined for competitive binding, perhaps due to limited sta-
bility of these nucleotides in RRL, whereas the drop-off in activity
was much less pronounced for sulfonamides 7a and 7b. RRLs were
then primed with bicistronic mRNAs where the initiation of
translation of the upstream Renilla cistron occurs in a cap-
dependent manner, while the translation of the downstream
ﬁreﬂy luciferase cistron is driven by the HCV internal ribosome
entry segment and is therefore independent of the cap structure at
the 50 end of the mRNA (Fig. 4). This bicistronic RNA allowed the
comparison of the effect of quinonlinone 14 and the para-carbox-
yphenyl sulfonamides 7a and 7b on cap-dependent and cap-
independent translation simultaneously. The data show that
while, as expected, there was inhibition of synthesis from the cap-
dependent Renillia luciferase mRNA, there was no effect on the
translation initiation of the ﬁreﬂy luciferase mediated by the HCV-
IRES, suggesting that sulfonamides 7a and 7b and quinolinone 14
inhibit cap-dependent translation (Fig. 4).
In order to investigate the effect of the eIF4E inhibitors on
overall protein synthesis in cells, we employed 35S-Met labelling
[50] to measure the amount of newly synthesised total protein in
HeLa cells after incubation for 24 h with test compounds (the
protein synthesis inhibitor puromycin was used as a positive con-
trol). None of the nucleoside phosphates (m7GMP and m7GTP) or
phosphate mimetics (7a and 7b) showed measurable inhibition of
cellular protein synthesis, indicating that membrane permeability
of the nucleoside phosphate mimetic compounds, including the
sulfonamides 7a and 7b, is still sub-optimal. Quinolinone 14, on the
other hand, whichwas the only virtual screening hit with activity in
the UV cross-linking assay, also inhibited protein synthesis in both
HeLa and MCF-7 cells with IC50 values similar to the activity levelsobserved in cell-free assays, suggesting that this compound is cell-
permeable. Based on the predicted physicochemical properties of
this compound (Table 2), this ﬁnding was not unexpected.
For quinolinone 14, which was observed to inhibit cellular
protein synthesis, we investigated if this effect was indeed due to
suppression of translation, as would be expected of an eIF4E cap-
binding inhibitor. For this purpose we used polysome analysis
[51]. HeLa cells were treated for 2 h with test compound 14 or
puromycin as a positive control, harvested, treated with cyclohex-
imide in order to trap RNAeribosome complexes, and cell lysates
were fractionated (Fig. 5a, ieiv). For cells treated with quinolinone
14, there was a decrease of the amount of RNA incorporated in
multiple ribosomes (polysomes) compared to untreated cells and a
concomitant increase in the sub-polysomal material, consistent
with a block in initiation (Fig. 5a and b), supporting our data which
shows 14 to suppress cap-dependent translation in cells.
To examine whether there was an effect on the expression of
proteins which are known to be eIF4E dependent and are associ-
ated with tumorigenesis, lysates of HeLa cells treated for 2 h with
quinolinone 14 were probed by western blotting for c-myc and
cyclin D1 protein, with actin used as a loading control. The data
show that at 50 and 100 mM treatment concentrations of 14 there
were decreases in levels of both proteins (Fig. 5c). To conﬁrm that
the decrease in protein levels corresponded with altered polysomal
association, mRNAs were isolated from polysomal and sub-
polysomal regions of the gradients and RT-PCR was used to assess
the relative amount of c-mycmRNA before and after treatment. The
data show that following treatment with quinolinone 14 there was
a small shift of the c-mycmRNA into the sub-polysomes, consistent
with a decrease in its translation (Fig. 5 aiv).
2.4. X-ray crystallography
eIF4E was co-crystallised with either an eIF4G- or a 4E-BP-
derived peptide (designated 4G and 4EBP, respectively) and one of
three of the m7GMP-derived analogues (squaramides 4a and 4f,
sulfonamide 7a). All complex structures showed the characteristic
cupped hand structure of eIF4E [52] with the ligands occupying the
cap-binding site.
The initial eIF4E:4G:7a complex structure (Fig. 6b and c) was
solved to a resolution of 1.71 Å (Table 3) with the ligand 7a residing
in the cap-binding site, accompanied by a single sulfate ion (from
the crystallisation buffer). The guanine of 7amakes three H-bonds,
two with the side chain of E103 and one with the backbone
carbonyl of W102. The sulfate ion interacts directly with eIF4E
through R157 and makes additional water-bridged interactions
with R112, N155, R157, and K162, as well as to the sulfonamide
group of 7a. The ligand 7a itself interacts with four neighbouring or
bridging waters. The unusual binding mode observed was unpre-
dicted as it was expected that the guanine would make the same or
similar cation-p stacking interaction as seen with all other cap-
based analogues to date (compare Fig. 6a) [12,15,20]. However,
the presence of the sulfate ion allows 7a to ‘fold0 back on itself and
the positively charged guanine forms a stabilising intramolecular
electrostatic interaction with the electronegative sulfonamide
group. In order to accommodate this ligand conformation, W102 is
reoriented out of the binding pocket from its normal cation-p
interaction position.W56 remains in the usual position, providing a
stacking interaction with the guanine. In comparison to other
complex structures with cap derivatives (Fig. 6a) the sulfate ion
occupies the same position as the a-phosphate. Presumably the
unusual bound conformation of 7a observed was favoured due to
high sulfate concentration in the crystallisation buffer.
In order to test this hypothesis, a crystal from these conditions
was transferred to an identical crystallisation drop but lacking
Fig. 4. Compounds 7a, 7b, and 14 inhibit cap-dependent translation, but not cap-independent translation driven by the HCV IRES: (a) Schematic of the construct containing the HCV
IRES. Cap-dependent translation drives expression from the Renilla luciferase transcript, whereas cap-independent translation drives protein synthesis from the Fireﬂy luciferase
transcript. (b) Rabbit reticulocyte lysates were primed with pRHCVF RNA and treated with compound 14 (i) or 7a or 7b (ii) at the doses shown. The compounds were dissolved in
DMSO, which is known to inhibit the reticulocyte lysate system when compared to the control without DMSO. Therefore a 1% solution of DMSO was used as an additional control
and the degree of inhibition measured relative to this value. Experiments were performed on three independent occasions, signiﬁcance (***P < 0.001) was calculated using Student's
t-test (error bars S.D.). Black bars denote Renilla luciferase and grey bars Fireﬂy luciferase.
Fig. 5. (ai and aii) Cells, either control (grey line) or treated with 25 mM compound 14 (pink line) were lysed and post-nuclear extracts were applied to 10e50% sucrose gradients to
allow the separation of actively translating ribosomes (polysomes) from subpolysomal material (e.g. 40S and 60S ribosomal subunits). (aiii) Analysis of the areas under the curves
attributable to the polysomes and subpolysomes in the control (ai) and treated (aii) samples showed a decrease in the amount of polysomes in treated cells and a concomitant
increase in the subpolysomal fractions. (aiv) To examine whether there was a decrease in the amount of c-myc mRNA associated with the polysomes following treatment with
compound 14, RT-qPCR was performed on individual fractions. The data show that there is a shift of c-myc mRNA to fractions that contain fewer polysomes indicative of trans-
lational repression of this mRNA. (b) To examine the effect of higher doses of compound 14 on polysome formation, cells were treated with 50 mM (pink line) and 100 mM (red line)
and gradients repeated. The data show a greater reduction in the amount of polysomal material under these conditions. (c) Western blot analyses of HeLa lysates treated for 2 h with
vehicle only (DMSO) or with compound 14 (20, 50 and 100 mM). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
F. Soukarieh et al. / European Journal of Medicinal Chemistry 124 (2016) 200e217206
Fig. 6. (a) eIF4E binding pose of Bn7GMP (PDB code 2V8X). (b) Binding pose of sulfonamide 7a, accompanied by a sulfate ion in eIF4E (crystallographic water molecules are
indicated by red spheres). (c) Electron density (red mesh, 0.53 electrons/Å3) contoured at 1.5 Å around ligand 7a and sulfate ion. (d) Binding pose of 7a following back-soaking (see
text). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 3
Crystallographic data.
eIF4E:4G:7a (PDB 5EI3) eIF4E:4G:7a back-soak (PDB 5EIR) eIF4E:4EBP:4a (PDB 5EKV) eIF4E:4G:4f PDB 5EHC)
Data collection
Resolution (Å) 1.71 2.69 3.61 2.40
Space group P21221 P21221 P212121 P21221
Unit cell (Å)
a 38.6 38.3 38.5 38.5
b 52.1 52.2 100.8 52.2
c 125.2 123.7 136.5 125.7
Unique reﬂectionsa 28165 (4039) 6814 (854) 6413 (889) 10425 (1466)
Completeness (%)a 100 (100) 93.8 (85.8) 97.8 (95.5) 99.7 (99.7)
Rmerge (%)a 9.4 (34.2) 16.0 (35.9) 28.2 (42.3) 19.2 (33.9)
I/sa 15.7 (5.3) 5.5 (3.0) 4.6 (3.1) 8.9 (5.3)
Reﬁnement
R (%) 16.6 24.8 26.8 21.8
Rfree (%) 18.7 27.2 34.1 26.4
Mean temperature factor B (Å2)b
eIF4E 14.1 24.7 17.1/20.8e 19.4
4G/4EBP 14.0 28.1 17.5/18.8e 19.2
Ligand 22.1 38.5 (36.9)d 18.4/24.1e 42.4
SO4 29.5 (46.1)d e e
Occupancy (%)b
Ligand 1.0 0.52 (0.48)d 0.88/0.74e 1.0
SO4 1.0 0.48 e e
All atoms used in reﬁnement 2103 1790 3265 1846
Water 355 32 0 139
Validationc (% of all residues)
Favoured 98.0 99.0 97.8 97.9
Allowed 100.0 100.0 100.0 100.0
Disallowed 0.0 0.0 0.0 0.0
a Values in parentheses refer to the highest-resolution shell.
b B-factor and occupancy reﬁnement were performed using Phenix.
c Validation was performed using MolProbity.
d Values in parenthesis refer to the lowest occupancy model.
e Values for both copies in the asymmetric unit.
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2.69 Å (Table 3) and shows that there is mixed occupancy for the
ligand. The occupancies for both conformations are almost equal
(52:48) with the higher occupancy conformation being one where
the triﬂuoromethylsulfonamide group occupies the a-phosphate
binding position (Fig. 6d), previously occupied by sulfate. As ex-
pected, the displacement of the sulfate was accompanied by
repositioning of W102 to form the usual cation-p ‘sandwich0
interaction with the positively charged guanine moiety and W56.
The squaramide complex structures eIF4E:4EBP:4a and eIF4E:4f
were solved to 3.61 Å and 2.40 Å, respectively (Table 3). Despite low
overall resolution, the eIF4E co-crystal structure with ligand 4a
clearly shows that the squaramide moiety acts as a phosphate
mimic by making a similar interactionwith R157 despite an altered
conformation (Fig. 7a). The positively charged N7-methyl guanine
system forms the characteristic cation-p interaction as expected.
Fig. 7b shows compound 4f bound to the cap-binding site of eIF4E.
The guanine group is located in its normal binding position,
stacking with the side-chain of W56. As predicted, the squaramide
occupies the a-phosphate position (Fig. 7c), making interactions
with the side-chain of R157. The chloro substituent of the N7-benzyl
group causes a rotation of approximately 90 in relation to other
N7-benzyl substituted cap analogues (Fig. 7c). In turn, to accom-
modate the extra space required by the chloro group, the side chain
of W102 is re-oriented away from making the usual cation-p
stacking interaction to a position similar to that seenwith 7a in the
presence of sulfate (compare Figs. 6b and 7b).
We were unable to obtain complex crystal structures with un-
ambiguous ligand density of the eIF4E inhibitors 12e16 from the
virtual screen. However, it is interesting to compare the predicted
binding modes of these compounds with the experimental eIF4E
complexes of them7GMP-derived derivatives (Fig. 8). Re-docking of
Bn7GMP to the receptor structure of the Bn7GMP complex using the
protocol used for virtual screening showed (Fig. 8a) virtually
identical positioning of the N7-benzylguanine portion of the ligand,
whereas the phosphate group in the re-docked pose bound more
deeply into the cavity behind W56 and making polar interactions
with the side chains of R157, W56, and D90, compared to the
experimental binding pose, in which the phosphate group only
interacts with R157. As a result of the different positioning of the
phosphate group, the ribose systems in the experimental and
modelled poses are also positioned somewhat differently.
The top-ranking docking solutions for the 4,5-bisaryl-2-
carboxymethylthio-1,2,3-triazoles 12aec all showed similar
poses, with the substituted phenyl groups stacking between W56
and W102, the unsubstituted aryl group inserting into the cavity
behind W102, and the carboxymethyl substituents occupying the
polar pocket behind W56 (Fig. 8b). Quinolinones 13 and 14 are
predicted to stack between W56 and W102 in a similar manner,Fig. 7. X-ray crystallographic eIF4E-binding poses of compound 4a (a) and 4f (b). (a) Alignm
and 4f (cyan). (For interpretation of the references to colour in this ﬁgure legend, the readdisposing the remaining substituents into the subpockets behind
the W residues as shown (Fig. 8c and d). Thiazolone 15 and the
pyridothiazolopyrimidine 16 again show stacked aromatic systems
involving W56 and W102 but these ligands do not show good in-
teractions with the other subpockets of the cap-binding site.
3. Conclusions
In the present studywe report a new set of nucleotide-based cap
analogues with phosphate modiﬁcations. Crystal structures of
sulfonamide 7a and squaramides 4a and 4f in complex with eIF4E
were obtained and show similar binding modes to cap derivatives
co-crystallised with eIF4E previously. However, our structures
highlight the ﬂexibility of the m7G-binding pocket, especially res-
idueW102 that forms part of the cation-p interaction characteristic
of cap-recognition by eIF4E. This ﬁnding suggests that cap-binding
inhibitors of eIF4E devoid of a permanent cationic structure may be
possible. All of the conﬁrmed eIF4E inhibitors (12a,14,16) from our
alternative design strategy based on virtual screening of lead-like
non-nucleotide compounds support this suggestion. We present
likely eIF4E-bindingmodes for these compounds but the possibility
that these induce conformational changes in the cap-binding
pocket of eIF4E cannot be excluded.
As has been found elsewhere [20,25], imparting sufﬁcient
membrane permeability in eIF4E cap-binding inhibitors for such
compounds effectively to block cellular eIF4E function is difﬁcult.
Despite modulation of the ionic and polar nature of the phosphate
group in m7GMP derivatives through replacement with phosphate
isosteres, none of our nucleoside monophosphate mimetic com-
pounds showed cellular activity. The situation was different with
the non-nucleotidic eIF4E inhibitors identiﬁed through virtual
screening. These compounds possess physicochemical properties
(Table 1) consistent with good permeability and we show that one
of these compounds, the quinolinone 14, not only inhibited eIF4E
cap-binding in a biochemical and cell-free functional assay, but also
acted as a protein synthesis inhibitor at the level of RNA translation
in cellular assays. Although compound 14 is not particularly lead-
like due to excessive ring count and lipophilicity, as well as low
intrinsic solubility (Table 1), our results conﬁrm for the ﬁrst time
that cellular eIF4E can be targeted with non-nucleotidic com-
pounds and inherently drug-like compounds.
4. Materials and methods
4.1. Chemistry
Flash chromatography was carried out using silica gel cartridges
(Sorbsil® and ISOLUTE®). TLC was performed using Merck silica gel
60 F254 plates and visualisation by UV irradiation at 254 nm or byent of experimental binding poses of Bn7GMP (PDB code 2V8X; green), 4a (magenta),
er is referred to the web version of this article.)
Fig. 8. Predicted eIF4E binding poses of compounds 12e16. (a) eIF4E binding pose of Bn7GMP as determined crystallographically (PDB code 2V8X; cyan), compared with re-docked
pose of Bn7GMP (green) using the same docking protocol as in the virtual screen. Docked poses of virtual hits (b) 12a (green), 12b (grey), and 12c (magenta); (c) 13; (d) 14; (e) 15);
(f) 16. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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13C-, 19F-, and 31P NMR spectra were obtained at room temperature
using a Bruker 400 Ultrashield spectrophotometer at 400.13 MHz,
100.61 MHz, 376.50 MHz, and 161.97 MHz, respectively. Samples
were prepared in the deuterated solvents Me2SO-d6 (unless
otherwise indicated). Chemical shifts (d) are expressed in ppm
relative to SiMe4. Mass spectra were obtained using a Waters 2759
spectrometer using both positive and negative electrospray ion-
isation. Infrared spectra were recorded on a Nicolet IR-200 FT-IR
spectrophotometer using the KBr disc technique. Analytical RP-
HPLC was performed with a Shimadzu UFLCXR system coupled to
a mass spectrometer (Applied Biosystems API2000). Phenomenex
columns thermostated at 40 C were used: C8-110A (method 1);
Luna 3u (PFP2) 110A, (method 2), and C18 (method 3); all with di-
mensions 50  2 mm. The ﬂow rate was 0.5 mL/min and UV
detection was at 220 and 254 nm. Gradient elution: pre-
equilibration for 1 min with 10% solvent B in solvent A, 10e98%
solvent B over 2 min, 98% B for 2 min, 98 to 10% B over 0.5 min, and
ﬁnally 10% B for 1 min (solvent A: 0.1% HCOOH in H2O, solvent B:
0.1% HCOOH inMeCN). Preparative RP-HPLCwas carried out using a
Waters automated LC system, with Waters 2525 pump, Waters
2767 sample manager, and Waters 2487 dual wavelength absor-
bance detector system or a Dionex ICS-3000 HPLC system with an
Ultimate-3000 detector, using Phenomenex Luna PFP or HILIC
(5 mM) columns (250 mm  10 mm). The purity of all compounds
screened in the biological assays was examined by LCMS analysis
and was found to be  95%.
4.2. N2-(4,40-dimethoxytrityl)-20,30-O-(1-methylethylidene)
guanosine (1b)
20,30-O-(1-Methyl-ethylidene)guanosine 1a (mp 202e204 C, lit
[53] > 200 C; 5 g, 15.5 mmol) was co-evaporated with pyridine
(3  30 mL) and dissolved in dry pyridine (100 mL) under N2.
Me3SiCl (9.8 mL, 77.4 mmol) was added over 5 min by syringe. The
solution was stirred for 3 h, when DMTrtCl (6.3 g, 18.5 mmol) was
added. Stirring (under N2) was continued for 21 h. The reactionwas
quenched with NH4OH (30 mL of a 35% solution in H2O). The
mixture was stirred for 2 h and evaporated. The residue was dis-
solved in EtOAc (100 mL) and the solution was washed with H2O,
brine, and aq NaHCO3 (50 mL each). The organic layer wasevaporated and the residue was chromatographed (SiO2;
CH2Cl2eMeOH, 9:1) to afford the title compound as a white solid
(76%). Mp 179e181 C. 1H NMR: d 10.66 (bs,1H, NH), 7.82 (s, 1H),
7.58 (s, 1H) 7.17e7.29 (m, 9H), 6.84e6.86 (m, 4H), 5.38 (d, J¼ 3.9 Hz,
1H), 4.76 (dd, J1 ¼ 6.2 Hz, J2 ¼ 3.9 Hz, 1H), 4.39 (dd, J1 ¼ 6.2 Hz,
J2 ¼ 2.4 Hz, 1H), 3.96 (td, J1 ¼ 6 Hz, J2 ¼ 2.4 Hz, 1H), 3.71 (s, 6H),
3.27e3.35 (m, 2H), 1.35 (s, 3H), 1.20 (s, 3H). 13C NMR: d 157.67,
156.39, 150.94, 149.29, 145.10, 136.93, 136.85, 136.61, 129.72, 129.61,
128.24, 127.61, 126.47, 117.39, 112.92, 88.86, 85.14, 81.78, 80.94,
69.48, 61.39, 54.94, 27.09, 25.45. IR (KBr): n 3342, 1685, 1607, 1568,
1508 cm1. MS (ESIþ): m/z [MþH]þ calcd for C34H36N5O7, 626.3;
found: 626.1.
4.3. 50-Deoxy-N2-(4,40-dimethoxytrityl)-50-iodo-20,30-O-(1-
methylethylidene)guanosine (1c)
A stirred solution of 1b (1 g, 1.6 mmol) in anhydrous THF
(100 mL) was cooled to 78 C. (PhO)3PþMeI (1.45 g, 3.2 mmol)
was added and the solution was allowed to reach r.t. over 30 min.
THF was evaporated and the residue was diluted with EtOAc
(50 mL). This solution was washed with Na2S2O3 (3  30 mL of a
25% solution in H2O). The organic phase was treated with MgSO4,
ﬁltered, and evaporated. The residue was dissolved in EtOAc
(15mL) and precipitatedwith hexane (100mL). The precipitate was
chromatographed (SiO2; CH2Cl2eMeOH, 9.2:0.8). The product was
again precipitated from EtOAcehexane to afford the title com-
pound as a white solid (70%). Mp 148e150 C. 1H NMR: d 10.76 (s,
1H, NH), 7.81 (s, 1H), 7.57 (s, 1H) 7.11e7.35 (m, 9H), 6.87e6.89 (d,
J ¼ 10 Hz, 4H), 5.53 (d, J ¼ 4.2 Hz, 1H), 4.66 (dd, J1 ¼ 4.2 Hz,
J2 ¼ 6.2 Hz, 1H), 4.18 (dd, J1 ¼ 6.2 Hz, J2 ¼ 2.4 Hz, 1H), 4.04 (td,
J1 ¼ 6.2 Hz, J2 ¼ 2.4 Hz, 1H), 3.75 (s, 6H), 2.77e2.91 (m, 2H), 1.40 (s,
3H), 1.21 (s, 3H). 13C NMR: d 157.81, 156.34, 151.09, 149.06, 144.95,
137.49, 136.85, 136.64, 129.59, 129.51, 128.19, 127.76, 126.70, 118.00,
113.44, 113.05, 113.03, 89.49, 83.72, 82.78, 80.45, 69.41, 55.00, 27.09,
25.52, 5.75. IR (KBr): n 3344, 1688,1606,1567,1508 cm1. MS (ESIþ):
m/z [MþH]þ calcd for C34H35IN5O6, 736.16; found, 736.14.
4.4. 50-Azido-50-deoxy-N2-(4,40-dimethoxytrityl)-20,30-O-(1-
methylethylidene)guanosine (1d)
To a stirred solution of 1c (1.95 g, 2.65 mmol) in dry DMF
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reaction was heated to 85 C for 24 h [CAUTION! Use of inorganic
azide: reaction carried out behind a safety shield]. After cooling, the
solution was evaporated and the residue was treated with H2O
(40 mL). The mixture was stirred for 30 min. The precipitate was
ﬁltered andwashedwith H2O (2 30mL) and Et2O (2 30mL) and
was then dried to afford the title compound as a white solid (77%).
Mp 136e138 C. 1H NMR: d 10.76 (bs, 1H, NH), 7.81 (s, 1H), 7.57 (s,
1H), 7.13e7.35 (m, 9H), 6.86e6.90 (m, 4H), 5.53 (d, J ¼ 3.9 Hz, 1H),
4.72 (dd, J1¼6.2 Hz, J2¼ 3.9 Hz,1H), 4.17 (dd, J1¼6.2 Hz, J2¼ 2.4 Hz,
1H), 4.04 (m, 1H), 3.75 (s, 6H), 3.00e3.08 (m, 2H), 1.38 (s, 3H), 1.21
(s, 3H). 13C NMR: d 157.80, 156.36, 151.12, 149.08, 144.97, 137.42,
136.84, 136.78, 129.58, 129.52, 128.20, 127.77, 126.65, 117.92, 113.34,
113.04, 89.04, 82.63, 81.14, 80.59, 69.40, 54.98, 51.36, 27.09, 25.53.
IR (KBr): n 3353, 2102, 1686, 1606, 1568, 1508 cm1. MS (EMIþ):m/z
[MþH]þ calcd for C34H35N8O6, 651.27; found, 651.24.4.5. 50-Amino-50-deoxy-N2-(4,40-dimethoxytrityl)-20,30-O-(1-
methylethylidene)guanosine (1e)
To a stirred solution of 1d (1 g,1.5 mmol) in dry pyridine (15 mL)
Ph3P (840 mg, 3.1 mmol) was added under N2 and the reaction was
stirred for 3 h. The mixture was cooled to 0 C and concentrated.
NH4OH (2.8 mL of 35% solution in H2O) was added. Stirring was
continued for 20 h, when the mixture was evaporated. The residue
was chromatographed (Si2O; CHCl3eMeOHeEt3N, 9:1:0.1) to afford
the title compound as awhite solid (48%). Mp 203e205 C. 1H NMR:
d 10.76 (bs, 1H, NH), 7.81 (s, 1H), 7.57 (s, 1H) 7.14e7.30 (m, 9H), 6.86
(dd, J1 ¼ 8.8 Hz, J2 ¼ 1.6 Hz, 4H), 5.45 (d, J ¼ 3.9 Hz, 1H), 4.76 (dd,
J1 ¼ 6.4 Hz, J2 ¼ 3.9 Hz, 1H), 4.23 (dd, J1 ¼ 6.4 Hz, J2 ¼ 3.0 Hz, 1H),
3.87e3.95 (m, 1H), 3.75 (s, 6H), 2.59e2.67 (m, 2H), 1.37 (s, 3H), 1.20
(s, 3H). 13C NMR: d 157.71, 156.35, 151.15, 149.17, 144.99, 137.19,
137.02, 129.62, 128.23, 127.68, 126.55, 117.66, 113.40, 112.97, 88.51,
83.40, 81.17, 81.10, 69.46, 55.00, 42.30, 27.11, 25.62. IR (KBr): n 3374,
1683, 1606, 1570, 1508 cm1. MS (ESIþ): m/z [MþH]þ calcd for
C34H37N6O6, 625.28; found, 625.26.4.6. 50-Deoxy-N2-(4,40-dimethoxytrityl)-50-(1,2-dioxo-3-
methoxycyclobut-3-en-4-yl)amino-20, 30-O-(1-methylethylidene)
guanosine (2)
To a stirred solution of 1e (300mg, 0.48mmol) inMeOH (25mL)
iPr2NEt (40 mL, 1.92 mmol) was added. After 5 min, dimethyl
squarate (68 mg, 0.48 mmol) was added to the reaction mixture,
which was stirred for 4 h. It was then evaporated and the residue
was chromatographed (Si2O; CHCl3eMeOH, 9:1) to afford the title
compound as a white solid (61%). Mp 170e172 C. 1H NMR: d 10.77
(s, 1H), 8.5e8.7 (m, 1H), 7.74 (s, 1H), 7.60 (s, 1H) 7.11e7.33 (m, 9H),
6.88 (d, J¼ 8.4 Hz, 4H), 5.49 (dd, J1¼14.4 Hz, J2¼ 4 Hz,1H), 4.61 (m,
J ¼ 3.6 Hz, 1H), 4.21e4.28 (m, 4H), 3.94 (m, J ¼ 2.4 Hz, 1H), 3.68 (s,
6H), 2.80e3.26 (m, 1H), 1.38 (s, 3H), 1.21 (s, 3H). 1H NMR (75 C):
d 10.61 (s, 1H), 8.41 (s, 1H), 7.68 (s, 1H), 7.42 (s, 1H), 7.16e7.31 (m,
9H), 6.83e6.88 (m, 4H), 5.46 (d, 1H, J ¼ 3.6 Hz), 4.8 (dd, 1H,
J1¼6.3 Hz, J2¼ 3.6 Hz), 4.33 (dd,1H, J1¼6.3 Hz, J2¼ 3.1 Hz), 4.24 (s,
3H), 4.00 (dd, 1H, J1 ¼ 6.3 Hz, J2 ¼ 3.1 Hz), 3.72 (s, 6H), 3.03 (s, 2H),
1.38 (s, 3H), 1.21 (s, 3H). 13C NMR: d 189.25, 189.04, 182.53, 177.62,
177.16, 172.29, 171.93, 157.78, 156.37, 151.04, 149.00, 145.01, 137.83,
136.95, 129.63, 129.50, 128.19, 127.82, 126.64, 118.07, 113.21, 113.06,
89.11, 88.95, 82.97, 82.58, 81.09, 80.93, 80.36, 80.19, 69.34, 60.10,
59.96, 54,97, 45.80, 45.14,27.15, 25.66. IR (KBr): n 3412, 2935, 1702,
1608, 1508 cm1. MS (ESIþ): m/z [MþH]þ calcd for C39H39N6O9,
735.28; found, 735.24.4.7. General method 1: N7-Alkylation of 50-amino-50-deoxy-N2-
(4,40-dimethoxytrityl)-20,30-O-(1-methylethylidene)guanosine
derivatives 2, 5, and 8
To a solution of compound 2, 5a, 5b, or 8 (1 eq) in DMF, the
appropriate alkyl or aryl halide (10 eq) was added and the mixture
was stirred for 24e48 h, with monitoring by TLC (CHCl3eMeOH,
17:3) and LC-MS. After completion of reaction, the mixture was
evaporated in vacuo and the residue was triturated with Et2O with
the aid of sonication. The precipitate was ﬁltered and chromato-
graphed (SiO2; CHCl3eMeOH, 9:1) to afford the pure title
compound.
4.8. 50-Deoxy-N2-(4,40-dimethoxytrityl)-50-(1,2-dioxo-3-
methoxycyclobut-3-en-4-yl)amino-N7-methyl-20,30-O-(1-
methylethylidene)guanosine (3a)
Using general method 1 from 2 andmethyl bromide.White solid
(57%). Mp 183e185 C. 1H NMR: d 9.88 (s, 1H), 8.78 (m,1H), 8.29 (m,
1H), 7.66e7.88 (m, 10H), 7.27e7.34 (m, 4H), 6.1 (m, 1H), 5.53 (m,
1H), 5.1 (m, 1H), 4.82 (m, 4H), 4.58 (s, 3H), 4.19e4.22 (m, 2H), 4.20
(s, 6H), 1.89 (s, 3H), 1.64 (s, 3H). 13C NMR: d 188.88, 188.58, 182,81,
177.31, 172.32, 171.82, 157.94, 157,85, 153.04, 147.17, 144.30, 138.09,
136.16, 129.69, 129.60, 128.22, 127.92, 126.90, 116.95, 113.16, 108.60,
91.65, 86.12, 85.77, 85.05, 80.94, 69.80, 60.27, 55.04, 45,64, 35.69,
26.74, 25.36. MS (ESIþ): m/z [M]þ calcd for C40H41N6O9, 749.29;
found, 749.26.
4.9. N7-Benzyl-50-deoxy-N2-(4,40-dimethoxytrityl)-50-(1,2-dioxo-3-
methoxycyclobut-3-en-4-yl)amino-20,30-O-(1-methylethylidene)
guanosine (3b)
Using general method 1 from 2 and benzyl bromide. White solid
(47%). Mp 182e185 C. 1H NMR: d 11.60 (s, 1H), 9.47 (s, 1H),
8.55e8.80 (m, 1H, NH), 8.14 (s, 1H), 7.14e7.42 (m, 14H), 6.82e6.85
(m, 4H), 5.6 (bs, 1H), 5.53 (m, 2H), 4.76e4.9 (m, 1H), 4.12e4.44 (m,
5H), 3.68 (s, 6H), 3.07 (m, 2H), 1.38 (s, 3H), 1.15 (s, 3H). 13C NMR:
d 189.29, 189.11, 182.69, 182.36, 177.91, 177.37, 172.26, 171.78, 157.80,
154.06, 147.70, 144.52, 137.37, 136.24, 134.10, 129.76, 129.67, 128.73,
128.68, 128.31, 127.79, 126.73, 116.91, 113.03, 107.80, 92.15, 86.32,
85.39, 81.04, 69.68, 60.25, 60.10, 54.97, 51.42, 45.40, 44.97, 26.79,
25.42. MS (ESIþ): m/z [M]þ calcd for C46H45N6O9, 825.32; found,
825.29.
4.10. 50-Deoxy-N2-(4,40-dimethoxytrityl)-50-(1,2-dioxo-3-
methoxycyclobut-3-en-4-yl)amino-N7-(3-methylbenzyl)-20,30-O-
(1-methylethylidene)guanosine (3c)
Using general method 1 from 2 and 3-methylbenzyl bromide.
Off-white solid (67%). 1H NMR: d 9.44 (s, 1H), 8.54e8.84 (m, 1H,
NH), 7.10e7.33 (m,14H), 6.79e6.88 (m, 4H), 5.64 (m,1H), 5.31e5.48
(m, 2H), 4.79e4.94 (m, 1H), 4.12e4.41 (m, 5H), 3.66 (s, 6H),
2.93e3.28 (m, 2H), 2.26 (s, 3H), 1.38 (s, 3H), 1.15 (s, 3H). 13C NMR:
d 189.29, 189.08, 182.63, 182.32, 177.91, 177.33, 172.24, 171.77, 157.76,
154.96, 154.69, 147.72, 144.62, 137.95, 137.23, 136.40, 133.97, 129.80,
129.72, 129.41, 128.63, 127.75, 126.66, 125.83, 112.99, 107.74, 92.18,
86.29, 85.29, 81.73, 69.69, 60.52, 60.10, 54.96, 51.30, 45.29, 44.95,
26.78, 25.46, 20.94. MS (ESIþ): m/z [M]þ calcd for C47H47N6O9,
839.3; found, 839.3.
4.11. 50-Deoxy-N2-(4,40-dimethoxytrityl)-50-(1,2-dioxo-3-
methoxycyclobut-3-en-4-yl)amino-N7-(3-methoxybenzyl)-20,30-O-
(1-methylethylidene)guanosine (3d)
Using general method 1 from 2 and 3-methoxybenzyl bromide.
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NH), 6.79e7.32 (m, 18H), 5.6 (m, 1H), 5.39e5.49 (m, 2H), 4.72e4.94
(m, 1H), 4.09e4.31 (m, 5H), 3.72 (s, 3H), 3.67 (s, 6H), 2.90e3.25 (m,
2H), 1.38 (s, 3H), 1.15 (s, 3H). 13C NMR: d 189.39, 189.05, 182.60,
182.28, 177.89, 177.38, 172.15, 171.85, 159.34, 157.72, 147.65, 144.70,
137.09, 136.50, 135.48, 129.90, 129.73, 128.30, 127.71, 126.62, 120.74,
118.43, 114.70, 113.9, 112.95, 107.85, 92.14, 86.73, 81.37, 79.16, 69.52,
60.19, 60.05, 55.08, 54.92, 51.16, 45.27, 44.97 26.74, 25.40. MS
(ESIþ): m/z [M]þ calcd for C47H47N6O10, 855.33; found, 855.32.
4.12. 50-Deoxy-N2-(4,40-dimethoxytrityl)-50-(1,2-dioxo-3-
methoxycyclobut-3-en-4-yl)amino-20, 30-O-(1-methylethylidene)-
N7-(3-(triﬂuoromethyl)benzyl)guanosine (3e)
Using general method 1 from 2 and 3-triﬂuoromethylbenzyl
bromide. White solid (76%). 1H NMR: d 9.43 (s, 1H), 8.52e8.82 (m,
1H, NH), 7.82e7.92 (m, 18H), 7.66e7.77 (m, 2H), 7.65e7.75 (m, 1H)
7.08e7.35 (m, 9H) 6.76e6.90 (m, 4H), 5.42e5.69 (m, 3H), 4.81e4.99
(m, 1H), 4.15e4.45 (m, 5H), 3.67 (s, 6H), 2.89e3.26 (m, 2H), 1.38 (s,
3H), 1.13 (s, 3H). 13C NMR: d 189.32, 189.06, 182.61, 182.29, 178.75,
177.33, 172.30, 172.22, 157.71, 147.82, 144.75, 136.51, 135.42, 133.04,
129.81,129.50,128.73,127.69,126.59,125.76,125.56,125.32,124.82,
122.62,118.12, 112.93,107.75, 92.31, 86.66, 85.46 81.09, 69.57, 60.08,
54.93, 50.70, 44.92, 26.72, 25.40. 19F NMR (DMSO-d6): d 60.98. IR
(KBr): n 3422, 2934, 1804, 1708, 1608, 1508 cm1. MS (ESIþ): m/z
[M]þ calcd for C47H44F9N6O9, 893.3; found, 893.2.
4.13. N7-(3-Chlorobenzyl)-50-deoxy-N2-(4,40-dimethoxytrityl)-50-
(1,2-dioxo-3-methoxy-cyclo-but-3-en-4-yl)amino-20,30-O-(1-
methylethylidene)guanosine (3f)
Using general method 1 from 2 and 3-chlorobenzyl bromide.
Off-white solid (63%). Mp 202e204 C. 1H NMR: d 9.39 (s, 1H),
8.50e8.89 (m, 1H, NH), 7.10e7.62 (m, 14H), 6.74e6.93 (m, 4H), 5.63
(s, 1 H), 5.38e5.56 (m, 2H), 4.60e5.00 (m, 1H), 4.08e4.55 (m, 5H),
3.68 (s, 6H), 2.93e3.28 (m, 2H), 2.26 (s, 3H), 1.39 (s, 3H), 1.15 (s, 3H).
13C NMR: d 189.32, 189.08, 182.64, 182.29, 177.94, 172.23, 171.81,
157.62, 147.87, 136.72, 136.45, 133.14, 130.49, 129.80, 129.75, 128.75,
128.46, 127.60, 126.46, 112.84, 107.65, 92.27, 90.43, 86,53 81.07,
69.48, 60.11, 54.92, 50.38, 45.65, 26.78, 25.46. IR (KBr): n 3424, 2933,
1803, 1709, 1606, 1508 cm1. MS (ESIþ): m/z [M]þ calcd for
C46H44ClN6O9, 859.3; found, 859.2.
4.14. 50-Deoxy-N2-(4,40-dimethoxytrityl)-50-(1,2-dioxo-3-
methoxycyclobut-3-en-4-yl)amino-N7-(4-ﬂuorobenzyl)-20,30-O-(1-
methylethylidene)guanosine (3g)
Using general method 1 from 2 and 4-ﬂuorobenzyl bromide.
White solid (47%). Mp: 200e202 C. 1H NMR: d 11.87 (s, 1H), 9.37 (s,
1H), 8.44e8.85 (m, 1H, NH), 7.46e7.55 (m, 3H) 7.08e7.36 (m, 11H)
6.75e6.95 (m, 4H), 5.61 (s, 1H), 5.48 (m, 2H), 4.73e4.90 (m, 1H)
4.12e4.45 (m, 5H), 3.68 (s, 6H), 2.90e3.26 (m, 2H), 1.38 (s, 3H), 1.15
(s, 3H). 13C NMR: d 189.47, 189.10, 182.58, 182.31, 178.49, 172.03,
161.01, 157.76, 154.56, 147.72, 144.90, 138.19, 137.38, 136.47, 131.14,
130.37, 129.73, 129.65, 128.29, 127.76,126.66, 115.66, 115.46, 113.00,
107.75, 92.13, 86.55, 81.01, 69.60, 60.10, 54.94, 50.81, 45.43, 26.76,
25.40. 19F NMR: d 113.08. MS (ESIþ): m/z [M]þ calcd for
C46H44FN6O9, 843.3; found, 843.2.
4.15. 50-Deoxy-N2-(4,40-dimethoxytrityl)-50-(1,2-dioxo-3-
methoxycyclobut-3-en-4-yl)amino-N7-(4-isopropylbenzyl)-20,30-O-
(1-methylethylidene)guanosine 3h
Using general method 1 from 2 and 4-isopropylbenzyl bromide.
White solid (46%). Mp 184e186 C. 1H NMR: d 9.41 (s, 1H),8.54e8.79 (m, 1H, NH), 7.11e7.38 (m, 14H), 6.75e6.91 (m, 4H), 5.63
(s, 1H), 5.32e5.52 (m, 2H), 4.73e4.91 (m, 1H), 4.09e4.41 (m, 5H),
3.67 (s, 6H), 2.86 (sp, J¼ 6.8 Hz,1H), 2.26 (s, 3H), 1.38 (s, 3H), 1.1e1.0
(m, 10H). 13C NMR: d 189.32, 189.13, 182.85, 177.96, 77.32, 172.24,
171.83, 157.78, 154.28, 149.09, 147.71, 147.70, 145.17, 136.62, 136.25,
131.57, 129.75, 128.82, 128.31, 127.78, 126.64, 113.01, 107.79, 92.15,
90.6, 86.25, 81.44, 81.08, 69.59, 59.75, 54.98, 51.12, 45.29, 33.16,
26.78, 25.43, 23.73. MS (ESIþ): m/z [M]þ calcd for C49H51N6O9,
867.4; found, 867.3.4.16. 50-Deoxy-N2-(4,40-dimethoxytrityl)-50-(1,2-dioxo-3-
methoxycyclobut-3-en-4-yl)amino-N7-(3,5-(di-tert-butyl)benzyl)-
20,30-O-(1-methylethylidene)guanosine (3i)
Using general method 1 from 2 to 3,5-(di-tert-butyl)benzyl
bromide. White solid (48%). Mp 210e212 C (dec). 1H NMR: d 9.51
(s, 1H), 8.56e8.82 (m, 1H, NH), 8.33 (m, 1H), 7.11e7.45 (m, 13H),
6.75e6.90 (m, 4H), 5.58 (m, 1H), 5.37e5.49 (m, 2H), 4.76e4.92 (m,
1H), 4.02e4.52 (m, 5H), 3.66 (s, 6H), 2.87e3.27 (m, 2H), 1.38 (s, 3H),
1.24 (s, 18H), 1.10 (s, 3H). 13C NMR: d 189.08, 182.59, 182.34, 177.92,
177.34, 172.24, 171.82, 157.73, 150.94, 147.74, 144.69, 136.39, 133.41,
129.84, 129.74, 128.40, 127.68, 126.63, 123.58, 122.58, 112.91, 107.91,
92.51, 86.82, 86.00, 81.65, 81.07, 69.67, 60.13, 54.91, 51.77, 45.23,
44.73, 34.55, 31.12, 26.70, 25.32. IR (KBr): n 3434, 2958, 1802, 1708,
1607, 1508 cm1. MS (ESIþ): m/z [M]þ calcd for C54H61N6O9, 937.4;
found, 937.4.4.17. General method 2: deprotection of 3ae3i
To a stirred solution of 3 (1 eq) in Me2CO, NaI (2 eq) was added
and the mixture was heated under reﬂux for 48 h. After completion
of the reaction, the solvent was evaporated and the residue was
treated with HCOOH (1 mL/0.1 mmol of 80% aq soln) for 12 h. After
cooling, the mixture was evaporated and the residue was triturated
with Me2CO with the aid of sonication. The precipitate was ﬁltered,
washed successively with Me2CO and hexane, and was dried.4.18. 50-Deoxy-50-(1,2-dioxo-3-hydroxycyclobut-3-en-4-yl)amino-
N7-methyl-guanosine (4a)
Using general method 2 from 3a. White solid (38%). Mp
192e194 C. 1H NMR: d 9.48 (s,1H), 8.11 (br s,1H), 7.14e7.19 (m,1H),
5.73 (d, J ¼ 6.3 Hz, 1H), 5.51 (br s, 2H), 4.76 (t, J ¼ 6.3 Hz, 1H),
4.13e4.22 (m, 2H), 4.02 (s, 3H), 3.98 (dd, J1¼4.8 Hz, J2¼ 2.6 Hz,1H),
3.46e3.52 (m,1H). 13C NMR: d 197.95, 188.93, 180.62, 157.19, 154.06,
148.95, 137.79, 108.39, 90.36, 85.76, 71.59, 70.56, 44.67, 35.60. IR
(KBr): n 3367, 1794, 1709, 1674, 1619, 1600, 1549, 1519 cm1. Anal.
RP-HPLC: tR 0.77 min (method 1, >95%). MS (ESIþ): m/z [M]þ calcd
for C15H17N6O7, 393.12; found, 393.11.4.19. N7-Benzyl-50-deoxy-50-(1,2-dioxo-3-hydroxy-cyclobut-3-en-
4-yl)amino-guanosine (4b)
Using general method 2 from 3b. White solid (35%). Mp
186e188 C. 1H NMR: d 11.70 (s, 1H), 9.75 (s, 1H), 7.52e7.57 (m, 2H),
7.36e7.43 (m, 3H), 7.11e7.18 (m, 1H), 5.76 (d, J¼ 6.0 Hz, 1H), 5.63 (s,
1H), 4.74 (d, J1 ¼ 10.8 Hz, J2 ¼ 5.8 Hz, 1H), 4.12e4.26 (m, 2H), 3.98
(dd, J1 ¼ 10.8 Hz, J2 ¼ 4.2 Hz, 1H), 3.48e3.53 (m, 1H). 13C NMR:
d 197.88, 189.00, 180.63, 156.74, 154.46, 149.28, 137.58, 134.48,
128.76, 128.63, 128.54, 107.58, 90.65, 85.66, 71.73, 70.60, 51.43,
44.72. IR (KBr): n 3394, 1791, 1706, 1632, 1606, 1532 cm1. Anal. RP-
HPLC: tR 2.33 min (method 1, >95%), tR 1.51 min (method 2, >94%).
MS (ESIþ): m/z [M]þ calcd for C21H21N6O7, 469.15; found, 469.14.
F. Soukarieh et al. / European Journal of Medicinal Chemistry 124 (2016) 200e2172124.20. 50-Deoxy-50-(1,2-dioxo-3-hydroxycyclobut-3-en-4-yl)amino-
N7-3-methylbenzyl-guano-sine (4c)
Using general method 2 from 3c. White solid (37%). Mp
187e190 C. 1H NMR: d 11.75 (br s, 1H), 9.80 (s, 1H), 7.28e7.35 (m,
2H), 7.15e7.22 (m, 1H) 7.06e7.15 (m, 1H), 5.77 (d, J ¼ 5.9 Hz, 1H),
5.57 (s, 2H), 4.73 (t, J ¼ 5.9 Hz, 1H), 4.13e4.22 (m, 4H), 3.98 (m, 1H),
3.47e3.58 (m, 1H), 2.30 (s, 3H). 13C NMR: d 197.70, 188.90, 180.55,
155.79, 153.21, 149.17, 138.21, 137.96, 134.22, 129.44, 129.06, 128.84,
125.62, 107.59, 90.71, 85.61, 71.79, 70.58, 51.49, 44.74, 20.97. Anal.
RP-HPLC: tR: 2.52 (method 1, >95%), tR: 1.98 min (method 2, >95%).
MS (ESIþ): m/z [M]þ calcd for C22H23N6O7, 483.16; found, 483.15.
4.21. 50-Deoxy-50-(1,2-dioxo-3-hydroxycyclobut-3-en-4-yl)amino-
N7-3-methoxybenzyl-guano-sine (4d)
Using general method 2 from 3d. White solid (36%). Mp
177e179 C. 1H NMR: d 11.69 (s, 1H), 9.78 (s, 1H), 7.32 (m, 1H),
7.07e7.14 (m, 3H), 6.95 (m, 1H), 5.77 (d, J ¼ 6.0 Hz, 1H), 5.58 (s, 2H),
5.51 (br s, 2H), 4.73 (t, J ¼ 6.0 Hz, 1H), 4.11e4.21 (m, 2H), 3.98 (m
1H), 3.75 (s, 3H), 3.49e3.55 (m, 1H). 13C NMR: d 197.50, 188.86,
180.38, 159.49, 155.74, 153.17, 149.17, 138.03, 135.64, 130.13, 120.60,
114.34, 114.18, 107.59, 90.71, 85.64, 71.75, 70.57, 55.17, 51.45, 44.74.
Anal. RP-HPLC: tR 2.42 min (method 1, >95%), tR 1.92 min (method
2, >95%). MS (ESIþ): m/z [M]þ calcd for C22H23N6O8, 499.16; found,
499.15.
4.22. 50-Deoxy-50-(1,2-dioxo-3-hydroxycyclobut-3-en-4-yl)amino-
N7-3-(triﬂuoromethyl)benz-yl-guanosine (4e)
Using general method 2 from 3e. The crude product was puriﬁed
by preparative HPLC using a Luna HILIC column tR 8.0 min; gradient
from 0% A to 100% A over 12.5 min, where A is 5:4:1
MeCNeH2Oe50 mM aq NH4HCOO pH 3.2, and B is 9:1
MeCNe50 mM aq NH4HCOO pH 3.2, to afford 4e as a white solid
(14.2%). Mp 221e224 C. 1H NMR: d 8.21 (s, 1H), 7.97 (s, 1H)
7.49e7.59 (m, 4H), 5.60e5.78 (m, 3H) 4.71 (dd, J1 ¼ 10.4 Hz,
J2¼ 4.8 Hz, 1H), 4.08e4.27 (m, 2H), 3.98 (dd, J1¼4.7 Hz, J2¼ 3.2 Hz,
1H), 3.48e3.55 (m, 1H). 13C NMR: d 197.79, 189.28, 181.22, 155.78,
153.24, 149.24, 138.20, 138.08, 135.47, 132.91, 130.07, 129.27, 125.60,
125.38, 107.58, 90.76, 85.54, 71.87, 70.52, 50.93, 44.69. 19F NMR:
d 61.02. Anal. RP-HPLC: tR: 2.67 min (method 1, >95%), tR 2.15 min
(method 2, >95%). MS (ESIþ): m/z [M]þ calcd for C22H20F3N6O7,
537.13; found, 537.13.
4.23. N7-3-Chlorobenzyl-50-deoxy-50-(1,2-dioxo-3-
hydroxycyclobut-3-en-4-yl)aminoguanosine (4f)
Using general method 2 from 3f. White solid (44%). Mp
193e195 C. 1H NMR: d 11.73 (s, 1H), 9.80 (s, 1H), 7.42e7.66 (m, 4H),
7.13e7.18 (m, 1H) 5.77 (d, J ¼ 6.0 Hz, 1H), 5.61 (s, 2H), 4.71 (t,
J ¼ 5.7 Hz, 1H), 4.11e4.21 (m, 2H), 3.98 (m, 1H), 3.52 (s, 3H),
3.51e3.56 (m, 1H). 13C NMR: d 197.30, 188.80, 180.34, 155.76, 153.16,
149.25, 138.17, 136.54, 133.34, 130.83, 128.78, 128.45, 127.37, 107.55,
90.74, 85.49, 71.94, 70.55, 50.85, 44.76. Anal. RP-HPLC: tR 2.54 min
(method 1, >95%), tR 2.02 min (method 2, >94%). MS (ESIþ): m/z
[M]þ calcd for C21H20ClN6O7, 503.11; found, 503.10.
4.24. 50-Deoxy-50-(1,2-dioxo-3-hydroxycyclobut-3-en-4-yl)amino-
N7-4-ﬂurobenzyl-guanosine (4g)
Using general method 2 from 3g. White solid (31%). 1H NMR:
d 9.69 (s, 1H), 7.64e7.70 (m, 2H), 7.23e7.26 (m, 4H), 5.74 (d,
J ¼ 5.9 Hz, 1H), 5.62 (s, 2H), 4.74 (dd, J1 ¼ 5.9 Hz, J2 ¼ 4.8 Hz, 1H),
4.12e4.25 (m, 2H), 3.98 (dd, J1¼7.1 Hz, J2¼ 3.2 Hz, 1H), 3.75 (s, 3H),3.46e3.52 (m,1H). 13C NMR: d 197.94,188.97,180.73, 158.03,156.09,
149.33, 136.87, 131.22, 131.14, 130.85, 115.83, 115.62, 107.50, 90.54,
85.54, 71.74, 70.61, 50.53, 44.76. 19F NMR: d113.16. Anal. RP-HPLC:
tR 2.44 min (method 1, >95%), tR 1.90 min (method 2, >95%). MS
(ESIþ): m/z [M]þ calcd for C21H20FN6O7, 487.14; found, 487.14.
4.25. 50-Deoxy-50-(1,2-dioxo-3-hydroxycyclobut-3-en-4-yl)amino-
N7-4-isopropylbenzyl-guanosine (4h)
Using general method 2 from 3h. White solid (11%). Mp
167e169 C. 1H NMR: d 9.64 (s, 1H), 8.23 (s, 1H), 7.48 (d, J ¼ 8.0 Hz,
2H), 7.27 (d, J ¼ 8.0 Hz, 3H), 5.73 (d, J ¼ 6.3 Hz, 1H), 5.30e5.60 (m,
4H), 4.79 (t, J ¼ 6.3 Hz, 1H), 4.09e4.30 (m, 2H), 3.96 (m, 1H),
3.45e3.51 (m, 1H), 2.87 (sp, J ¼ 6.8 Hz, 1H), 1.17 (d, J ¼ 6.8 Hz, 6H).
13C NMR: d 197.78, 188.98, 180.52, 155.77, 153.16, 149.10, 147.89,
137.85, 135.17, 128.69, 127.50, 126.83, 126.48, 107.50, 90.71, 85.62,
71.79, 70.55, 51.27, 44.68, 33.17, 33.09, 23.79, 23.73. Anal. RP-HPLC:
tR: 2.73 min (method 1, >95%), tR 2.21 min (method 2, >95%). MS
(ESIþ): m/z [M]þ calcd for C24H27N6O7, 511.19; found, 511.19.
4.26. N7-3,5-(di-tert-butyl)benzyl-50-deoxy-50-(1,2-dioxo-3-
hydroxycyclobut-3-en-4-yl)amino-guanosine (4i)
Using general method 2 from 3i. White solid (15%). 1H NMR:
d 9.53 (s, 1H), 8.40 (s, 2H), 8.28 (s, 1H), 7.45 (d, J ¼ 1.65 Hz, 2H), 7.37
(m, 1H), 5.73 (d, J ¼ 6.9 Hz, 1H), 5.62 (s, 2H), 4.89 (dd, J1 ¼ 6.9 Hz,
J2 ¼ 4.8 Hz, 1H), 4.21 (td, J1 ¼ 8.1 Hz, J2 ¼ 3.2 Hz, 1H), 4.14 (dd,
J1 ¼ 4.8 Hz, J2 ¼ 3.2 Hz, 1H), 3.96 (dd, J1 ¼ 4.8 Hz, J2 ¼ 1.8 Hz, 1H),
3.40 (m, 1H), 1.26 (s, 18H). 13C NMR: d 198.14, 188.89, 180.75, 165.84,
150.93, 150.61, 149.23, 135.27, 134.31, 123.01, 122.20, 107.92, 90.46,
86.06, 70.93, 70.83, 51.30, 44.88, 31.19. Anal. RP-HPLC: tR 3.07 min
(method 1, >86%), tR 2.54 min (method 2, >95%). MS (ESIþ): m/z
[M]þ calcd for C29H37N6O7, 581.27; found, 581.27.
4.27. 50-Deoxy-N2-(4,40-dimethoxytrityl)-20,30-O-(1-
methylethylidene)-50-(triﬂuoromethyl-sulfamoyl)guanosine (5a)
To a stirred solution of 1e (200 mg, 0.32 mmol) in dry CH2Cl2
(10 mL), Et3N (128 mL, 1.28 mmol) was added. The mixture was
cooled to 0 C and CF3SO2Cl (33 mL, 0.32 mmol) was added drop-
wise via syringe. After stirring for 48 h, the mixture was evapo-
rated and the residue was chromatographed (Si2O; CHCl3eMeOH,
9:1) to afford the title compound as a yellow oil (49%). 1H NMR:
d 10.78 (s, 1H), 9.70 (s, 1H), 7.82 (s, 1H), 7.63 (s, 1H), 7.13e7.34 (m,
9H), 6.88 (d, J ¼ 7.5 Hz, 4H), 5.54 (d, J ¼ 4.0 Hz, 1H), 4.72 (dd,
J1 ¼ 6.2 Hz, J2 ¼ 4.0 Hz, 1H), 4.19 (dd, J1 ¼ 6.2 Hz, J2 ¼ 3.1 Hz, 1H),
3.87e3.93 (m, 1H), 3.72 (s, 6H), 2.93e3.09 (m, 2H), 1.39 (s, 3H), 1.21
(s, 3H). 13C NMR: d 157.87, 156.47, 151.20, 149.22, 145.06, 137.49,
137.08, 136.89, 129.65, 129.60, 128.30, 127.78, 126.66, (q, J ¼ 324 Hz,
124 Hz, 121 Hz, 118 Hz, 115 Hz, CF3), 124.35, 121.15, 117.94, 114.74,
117.89, 113.83, 113.08, 88.58, 82.91, 80.83, 80.81, 69.52, 54.98, 45.11,
27.16, 25.71. 19F NMR: d 77.46. MS (ESIþ): m/z [MþH]þ calcd for
C35H36F3N6O8S, 757.2; found, 757.2.
4.28. 50-(4-Carboxyphenyl)sulfamoyl-50-deoxy-N2-(4,40-
dimethoxytrityl)-20,30-O-(1-methyl-ethylidene)guanosine (5b)
To a stirred solution of 6e (300 mg, 0.48 mmol) in CH2Cl2
(25 mL) Et3N was added (254 mL, 1.92 mmol). After cooling to 0 C,
4-carboxybenzenesulfonyl chloride (105 mg, 0.48 mmol) was
added and the mixture was allowed to reach r.t. and was stirred for
24 h. It was evaporated and the residue was chromatographed
(Si2O; CH2Cl2eMeOH, 8.5:1.5) to afford the title compound as a
white solid (73%). 1H NMR: d 10.92 (bs, 1 H), 8.08 (dd, J1 ¼ 6.8 Hz,
J2 ¼ 1.7 Hz, 2 H), 7.79 (dd, J1 ¼ 6.8 Hz, J2 ¼ 1.7 Hz, 2 H), 7.77 (s, 1 H),
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J ¼ 4.1 Hz, 1 H), 4.74 (dd, J1 ¼ 6.4 Hz, J2 ¼ 4.1 Hz, 1H), 4.14 (dd,
J1 ¼ 6.4 Hz, J2 ¼ 3.1 Hz, 1 H), 3.83 (td, J1 ¼ 6.4 Hz, J2 ¼ 3.1 Hz, 1 H),
3.68 (s, 6H), 2.67e2.74 (m, 2 H), 1.33 (s, 3 H), 1.17 (s, 3 H). 13C NMR:
d 173.09, 157.66, 151.19, 149.11, 144.97, 140.37, 137.16, 136.26, 129.85,
129.53, 128.17, 127.60, 126.25, 124.71, 117.71, 113.59, 112.92, 88.39,
82.69, 80.97, 69.44, 59.82, 44.42, 27.87, 25.58. IR (KBr): n 3314, 2985,
2674, 2488, 1685, 1605, 1570, 1508 cm1. MS (ESIþ): m/z [MþH]þ
calcd for C41H41N6O10 S 809.26 found: 809.23.
4.29. N7-Benzyl-50-deoxy-N2-(4,40-dimethoxytrityl)-20,30-O-(1-
methylethylidene)-50-(triﬂuoro-methylsulfamoyl)guanosine (6a)
Using general method 1 from 5a and benzyl bromide. Light
yellow solid (53%). 1H NMR: d 11.42 (br s, 1H), 10.11 (s, 1H), 8.18 (s,
1 H), 7.45e7.53 (m, 2H), 7.15e7.41 (m, 13H), 6.74e6.93 (m, 4H),
5.34e5.51 (m, 3H), 4.99 (dd, J1 ¼ 5.8 Hz, J2 ¼ 1.3 Hz, 1H), 4.65 (d,
J ¼ 5.7 Hz, 1H), 4.30e4.39 (m, 1H), 3.70 (s, 6H), 3.03e3.10 (m, 2H),
1.37 (s, 3H), 1.11 (s, 3H). 13C NMR: d 157.71, 152.92, 147.71, 144.44,
137.76,136.24,136.08,134.33,129.89,129.73,128.88,128.62,128.35,
127.60, 126.58, 112.90, 112.84, 111.86, 106.78, 92.42, 89.39, 83.96,
81.86, 69.69, 54.90, 51.53, 47.55, 43.65, 26.66, 24.97. 19F NMR:
d 76.09. IR (KBr): n 3430, 2933, 1706, 1607, 1509. MS (ESIþ): m/z
[M]þ calcd for C42H42F3N6O8S, 847.27; found, 847.25.
4.30. 50-(4-Carboxyphenyl)sulfamoyl-50-deoxy-N2-(4,40-
dimethoxytrityl)-N7-methyl-20,30-O-(1-methylethylidene)guanosine
(6b)
Using general method 1 from 5b and methyl iodide. The crude
product was puriﬁed by SiO2 column chromatography (CHCl3e-
MeOH, 7.5:2) to furnish pure title compound as a white solid (61%).
1H NMR (MeOH-d4): d 8.13 (d, J¼ 8.4 Hz, 2H) 7.85 (d, J¼ 8.4 Hz, 2 H),
7.16e7.38 (m, 9 H), 6.77e6.87 (m, 4H), 5.60 (d, J ¼ 1.2 Hz,1 H), 5.09
(dd, J1 ¼ 6 Hz, J2 ¼ 2 Hz, 1 H), 4.33 (dd, J1 ¼ 6 Hz, J2 ¼ 1.7 Hz, 1 H),
4.26 (td, J1 ¼ 6 Hz, J2 ¼ 1.7 Hz, 1 H), 4.07 (s, 3 H) 3.74 (s, 6 H),
2.76e2.90 (m, 2H), 1.41 (s, 3 H), 1.11 (s, 3 H). 13C NMR (MeOH-d4):
d 160.08, 153.04, 149.21, 143.94, 139.37, 137.58, 131.27, 131.22,
129.88, 129.33, 128.99, 128.18, 127.78, 114.87, 114.23, 113.99, 113.02,
95.08, 88.21, 84.35, 83.41, 72.10, 65.31, 55.74, 36.65, 27.13, 25.82. MS
(ESIþ): m/z [Mþ2H]þ calcd for C42H45N6O10S, 823.3; found, 823.2.
4.31. N7-Benzyl-50-(4-carboxyphenyl)sulfamoyl-50-deoxy-N2-(4,40-
dimethoxytrityl)-20,30-O-(1-methylethylidene)guanosine (6c)
Using general method 1 from 5c and benzyl bromide. The crude
product was puriﬁed by SiO2 column chromatography (CHCl3e-
MeOH, 8:2) to furnish pure title compound as a white solid (58%).
1H NMR (MeOH-d4): d 9.16 (s,1H), 8.14 (d, J ¼ 8.5 Hz, 2 H), 7.80 (d,
J¼ 8.5 Hz, 2H), 7.49e7.54 (m, 2 H), 7.35e7.39 (m, 3 H), 7.16e7.36 (m,
9 H), 6.74e6.83 (m, 4H), 5.54e5.68 (m, 3H), 5.04 (dd, J1 ¼ 6.1 Hz,
J2 ¼ 1.7 Hz, 1 H), 4.27 (dd, J1 ¼ 6.1 Hz, J2 ¼ 2.0 Hz, 1H), 4.17e4.23 (m,
1 H), 3.73 (s, 6 H), 2.75e2.86 (m, 2H), 1.39 (s, 3H), 1.10 (s, 3H). 13C
NMR (MeOH-d4): d 160.08, 154.91, 149.52, 145.95, 143.85, 137.61,
135.27, 131.22, 131.19, 129.87, 129.51, 129.01, 128.20, 127.78, 114.98,
114.25, 114.17, 109.76, 95.04, 88.06, 84.17, 82.94, 72.10, 55.73, 53.74,
43.81, 27.14, 25.87. MS (ESIþ): m/z [M]þ calcd for C48H47N6O10S,
899.3; found, 899.2.
4.32. General method 3: deprotection of 6ae6c and 9ae9b
A solution of 6 or 9 in HCOOH (1 mL/0.1 mmol of 80% aq solu-
tion) was stirred for 12 h. The mixture was evaporated and the
residue was triturated with Me2CO with the aid of sonication. The
precipitate was ﬁltered, washed successively with Me2CO andhexane, and was dried.
4.33. N7-Benzyl-50-deoxy-50-(triﬂuoromethylsulfamoyl)guanosine
(7a)
Using general method 3 from 6a. The crude product was puriﬁed
by preparative HPLC using a Luna PFP column (tR 4.9 min; isocratic
elution at 35% B in A, where A is 0.1% CF3COOH in H2O, and B is 0.1%
CF3COOH in MeCN) to afford 7a as a white solid (26%). 1H NMR:
d 9.27 (s, 1H), 7.49e7.56 (m, 2H), 7.36e7.44 (m, 3H), 5.94 (d,
J ¼ 4.0 Hz, 1H), 5.66 (dd, J1 ¼ 21.0 Hz, J2 ¼ 14.4 Hz, 2H), 4.19 (dd,
J1 ¼ 5.2 Hz, J2 ¼ 4.0 Hz, 1H), 4.29 (t, J ¼ 5.2 Hz, 1H), 4.13e4.17 (m,
1H), 3.57e3.63 (m, 2H). 13C NMR: d 157.48, 154.98, 151.33, 134.99,
130.38, 130.27, 129.81, 122.94, 119.75, 109.10, 92.73, 85.28, 74.84,
72.12, 53.63, 46.45. 19F NMR: d 76.39. Anal. RP-HPLC: tR 2.63 min
(method 1, >95%), tR 2.23 min (method 2, >63%). MS (ESIþ): m/z
[M]þ calcd for C18H20F3N6O6S, 505.11; found, 505.11.
4.34. 50-(4-Carboxyphenyl)sulfamoyl-50-deoxy-N7-
methylguanosine (7b)
Using general method 3 from 6b. The crude product was puri-
ﬁed by preparative HPLC using a LUNA PFP column (tR 4.0 min,
gradient of 5%e50% B in A over 15 min, where A is 0.1% CF3COOH in
H2O, and B is 0.1% CF3COOH in MeCN) to afford 7b as a white solid
(44%). 1H NMR (DMSO-d6 and D2O): d 9.26 (s, 1H), 8.28 (s, 1H), 8.11
(s, 1H), 8.00 (d, J¼ 7.7 Hz, 2H), 7.76 (d, J¼ 7.7 Hz, 2H), 7.58 (br s, 2H),
5.75 (d, J¼ 4.8 Hz,1H), 4.50 (t, J¼ 4.8 Hz,1H), 4.06 (t, J¼ 4.8 Hz,1H),
4.01 (s, 3H), 3.97 (dd, J1 ¼ 9.6 Hz, J2 ¼ 4.8 Hz), 3.10 (m, 2H, H50). 13C
NMR (DMSO-d6 and D2O): d 173.36, 171.03, 149.41, 140.95, 140.23,
129.31, 127.48, 126.57, 125.85, 109.03, 90.32, 83.60, 72.82, 70.51,
43.70, 35.74. Anal. RP-HPLC: tR 1.09 min (method 1, >95%), tR
0.77 min (method 2, >95%). MS (ESIþ): m/z [M]þ calcd for
C41H40N6O10S, 481.11; found, 481.11.
4.35. N7-Benzyl-50-(4-carboxyphenyl)sulfamoyl-50-
deoxyguanosine (7c)
Using general method 3 from 6c. The crude product was puriﬁed
by RP-HPLC with a LUNA PFP column (tR 19.8 min, gradient of 10%e
30% B in A over 20 min, where A is 0.1% CF3COOH in H2O, and B is
0.1% CF3COOH inMeCN) to afford 7c as awhite solid (38%). 1H NMR:
d 9.56 (s, 1H), 8.11 (s, 1H), 8.06 (d, J ¼ 8.4 Hz, 2H), 7.87 (d, J ¼ 8.4 Hz,
2H), 7.37e7.51 (m, 7H), 5.79 (d, J ¼ 4.4 Hz, 1H), 5.59 (s, 2H), 4.50 (t,
J¼ 4.8 Hz, 1H), 4.09 (t, J¼ 4.8 Hz,1H), 3.89e4.02 (m,1H), 3.09e3.24
(m, 2H). 13C NMR: d 166.17, 155.77, 153.16, 149.62, 144.32, 136.48,
134.30, 130.00, 128.84, 128.20, 126.70, 106.79, 89.14, 83.71, 73.45,
70.58, 51.61, 49.29. Anal. RP-HPLC: tR 2.49 min (method 1, >95%), tR
2.09 min (method 2, >95%). MS (ESIþ): m/z [M]þ calcd for
C24H25N6O8S, 577.14; found, 577.14.
4.36. 50-(tert-Butyloxycarbamoyl)-50-deoxy-N2-(4,40-
dimethoxytrityl)-20,30-O-(1-methylethyli-dene)guanosine (8)
To a stirred solution of 1e (0.5 g, 0.8 mmol) in CH2Cl2 (30 mL)
was added Et3N (220 mL, 1.6 mmol). The mixture was cooled to 0 C
and Boc2O (170 mg, 0.8 mmol) was added. Stirring was continued
for 3 h, when themixturewas evaporated. The residue was puriﬁed
by SiO2 column chromatography (CH2Cl2eMeOH, 9:1) to afford
pure title compound as a white solid (375 mg, 65%). 1H NMR:
d 10.66 (s, 1H, NH), 7.76 (s, 1H), 7.58 (s, 1H) 7.10e7.33 (m, 9H),
6.83e6.89 (d, J ¼ 8.5 Hz, 4H), 5.36 (d, J ¼ 3.9 Hz, 1H), 4.76 (dd,
J1 ¼ 6.0 Hz, J2 ¼ 3.9 Hz, 1H), 4.27 (m, 1H), 3.82 (m, 1H), 3.70 (s, 6H),
2.61e2.87 (m, 2H), 1.38 (s, 9H), 1.35 (s, 3H), 1.18 (s, 3H). 13C NMR:
d 157.73, 156.38, 155.55, 150.95, 149.23, 145.08, 137.22, 136.97,
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88.68, 82.41, 81.33, 80.38, 77.91, 69.39, 54.96, 41.85, 28.17, 27.16,
25.57. MS (ESIþ): m/z [MþH]þ calcd for C39H45N6O8, 725.33; found,
725.32.
4.37. 50-(tert-Butyloxycarbamoyl)-50-deoxy-N2-(4,40-
dimethoxytrityl)-N7-methyl-20,30-O-(1-methylethylidene)guanosine
(9a)
Using general method 1 from 8 and methyl iodide. Yellow
powder (98%). Mp 106e107 C. 1H NMR: d 11.48 (s, 1H, NH), 9.20 (s,
1H), 8.07 (s, 1H) 7.15e7.34 (m, 9H), 6.89 (m, 1H), 6.86 (d, J ¼ 8.9 Hz,
4H), 5.45 (d, J ¼ 2.1 Hz, 1H), 4.82 (dd, J1 ¼ 6.1 Hz, J2 ¼ 2.1 Hz, 1H),
4.39 (dd, J1¼6.1 Hz, J2¼ 1.4 Hz, 1H), 4.08 (m,1H), 3.93 (m, 3H), 3.71
(s, 6H), 2.72e3.03 (m, 2H), 1.38 (s, 9H), 1.35 (s, 12H), 1.10 (s, 3H). 13C
NMR: d 157.89, 155.63, 152.80, 147.19, 144.32, 137.82, 136.10, 136.03,
129.74, 129.66, 128.26, 127.81, 126.81, 113.07, 112.75, 108.54, 92.19,
86.13, 82.00, 81.33, 78.18, 69.81, 55.02, 41.63, 35.62, 28.11, 26.61,
25.14. MS (ESIþ): m/z [M]þ calcd for C40H47N6O8, 739.34; found,
739.34.
4.38. N7-Benzyl-50-(tert-butyloxycarbamoyl)-50-deoxy-N2-(4,40-
dimethoxytrityl)-20,30-O-(1-methylethylidene)guanosine (9b)
Using general method 1 from 8 and benzyl bromide. The crude
product was puriﬁed by SiO2 column chromatography (CHCl3e-
MeOH, 9:1) to afford the title compound as a white powder (73%).
1H NMR ((CD3)2CO): d 10.11 (s, 1H), 7.02e7.67 (m, 15H), 6.66e6.94
(m, 4H), 6.45e6.65 (t, J ¼ 5.9 Hz, 1H), 5.42e5.77 (m, 3H), 5.12 (m,
1H), 4.72 (m, 1H), 4.22e4.44 (m, 1H), 3.67 (s, 6H), 3.14e3.48 (m,
2H), 1.43 (s, 3H), 1.40 (s, 9H), 1.17 (s, 3H). 13C NMR ((CD3)2CO):
d 158.99, 157.32, 157.10, 149.16, 146.44, 138.26, 138.18, 136.48,
135.60, 131.44, 131.37, 130.02, 129.57, 129.46, 128.16, 127.08, 114.08,
113.42, 108.70, 93.82, 89.03, 84.51, 82.73, 79.29, 71.32, 55.37, 52.32,
43.47, 34.40, 28.63, 27.53, 26.03. MS (ESIþ): m/z [M]þ calcd for
C46H51N6O8, 815.4; found, 815.3.
4.39. 50-Amino-50-deoxy-N7-methylguanosine (10a)
Using general method 3 from 9a. After completion of the reac-
tion the solvent was evaporated and the residue was suspended in
H2O and extracted with CHCl3. The combined extracts were dried
(MgSO4) and evaporated. The residue was puriﬁed by preparative
HPLC using a Luna HILIC column (tR 8.0 min; gradient from 0% A to
100% A over 12.5 min, where A is 5:4:1 MeCNeH2Oe50 mM aq
NH4HCOO pH 3.2, and B is 9:1 MeCNe50mM aq NH4HCOO pH 3.2)
to afford the title compound as a white solid (51%). 1H NMR: d 9.32
(s, 1H), 8.26 (s, 2H), 6.99 (br s, 2H), 5.82 (dd, J ¼ 4.7 Hz, 1H), 4.47 (t,
J ¼ 4.7, 1H), 4.18 (t, J ¼ 4.7 Hz, 1H), 4.18 (t, J ¼ 4.7 Hz, 1H), 4.04 (m,
1H), 4.00 (s, 3H), 3.41 (m, 2H). 13C NMR: d 158.68, 156.83, 149.26,
135.39,107.69, 89.51, 82.52, 73.43, 70.57, 40.94, 35.46. MS (ESIþ):m/
z [M]þ calcd for C11H17N6O4, 297.13; found, 297.13.
4.40. 50-Amino-N7-benzyl-50-deoxyguanosine (10b)
Using general method 3 from 9b. The crude product was tritu-
rated with Me2CO and the colourless precipitate was ﬁltered and
dried (44%). 1H NMR: d 8.50 (s,1H), 7.51e7.61 (m, 2H), 7.32e7.43 (m,
3H), 5.98 (d, J¼ 4.4 Hz, 2H), 5.70 (s, 2H), 4.87 (t, J¼ 4.4 Hz, 1H), 4.38
(m, 1H), 4.32 (m, 1H), 3.36e3.64 (m, 2H). 13C NMR: d 157.18, 154.77,
149.61, 136.66, 134.65, 128.90, 128.77, 128.38, 106.99, 90.31, 81.50,
73.10, 70.85, 51.40, 40.80. Anal. RP-HPLC: tR 3.51 min (method 1,
>95%). MS (ESIþ): m/z [M]þ calcd for C17H21N6O4, 373.2; found,
373.2.4.41. 50-Deoxy-N7-methyl-50-((1H-tetrazol-5-yl)methylcarbamoyl)
guanosine (11a)
To a stirred solution of 10a (15 mg, 0.05 mmol) in DMF (1 mL)
were added Et3N (8 mL, 0.05 mmol), N,N0-diisopropylcarbodiimide
(8 mL, 0.05 mmol), and 1H-tetrazole-5-acetic acid (7 mg,
0.05 mmol). The mixturewas stirred for 24 h at r.t. and diluted with
Me2CO (10 mL). The precipitate was collected, dried, and puriﬁed
by preparative HPLC using a Luna HILIC column (gradient from 0% A
to 100% A over 12.5 min, where A is 5:4:1 MeCNeH2Oe50 mM aq
NH4HCOO pH 3.2, and B is 9:1 MeCNe50mM aq NH4HCOO pH 3.2)
to afford the title compound as a white solid (3 mg, 14%). 1H NMR
(D2O): d 8.26 (s, 1H), 5.77 (d, J ¼ 4.3 Hz, 1H), 4.72 (t, J ¼ 4.3 Hz, 1H),
4.51 (m, 2H), 4.09 (m, 2H), 3.88 (s, 3H), 3.76 (s, 2H), 3.47 (m, 2H). 13C
NMR (D2O): d 171.20, 163.14, 162.86, 155.40, 155.08, 149.44, 108.68,
90.23, 83.33, 73.67, 70.69, 40.39, 35.79, 31.89. Anal. RP-HPLC: tR
0.67 min (method 1: >95%), tR 0.33 min, (method 2, >95%.) MS
(ESIþ): m/z [Mþ] calcd for C14H19N10O5, 407.15; found, 407.16.
4.42. N7-Benzyl-50-deoxy-50-((1H-tetrazol-5-yl)methylcarbamoyl)
guanosine (11b)
This compound was obtained from 10b analogously to prepa-
ration and puriﬁcation of 11a (34%). 1H NMR: d 10.19 (s, 1H), 8.38 (t,
J¼ 5.6 Hz,1H), 8.31 (s, 2H), 7.74 (s, 1H), 7.49e7.58 (m, 2H), 7.21e7.41
(m, 3H), 5.85 (d, J ¼ 5.3 Hz, 1H), 5.75 (dd, J1 ¼ 20.0 Hz, J2 ¼ 15.0 Hz,
1H), 4.40 (t, J ¼ 5.2 Hz, 1H), 4.06 (m, 2H), 3.34e3.67 (m, 4H). 13C
NMR: d 169.95, 165.46, 158.39, 155.95, 150.63, 136.32, 135.42,
129.19, 129.00, 128.92, 107.00, 88.05, 84.92, 74.52, 70.80, 51.77,
40.90, 34.05. Anal. RP-HPLC: tR 1.40 min (method 1, >95%), tR
0.77 min (method 2, >95%). MS (ESIþ): m/z [Mþ] calcd for
C20H23N10O5, 483.18; found, 483.15.
4.43. Virtual screening
An eIF4EeBn7GMP complex crystal structure (PDB code 2V8X)
[15] was used for docking purposes, and docking was based on the
lead-like subset of compounds in the ZINC database [40]. Receptor
preparationwas performed using the Biopolymer function in SYBYL
8.0 (Tripos International, 1699 South Hanley Rd., St. Louis, MO,
63144, USA). The entire binding site occupied by Bn7GMP in the
eIF4E template structure was deﬁned as the docking site. Ligand 3D
co-ordinates were generated using CONCORD (R. S. Pearlman,
“Concord,” distributed by Tripos International, St. Louis, MO, 63144,
USA). Conformer (up to 200 per compound) generation (OMEGA
version 2.4.6) [54,55], as well as docking and scoring (FREDmodule
of the OEDocking version 3.0.0) [41,42], were carried out using
OpenEye Scientiﬁc Software (Santa Fe, NM, USA; http://www.
eyesopen.com). Scoring of docked poses was performed using a
combination of the OEDocking scoring functions Chemgauss3 and
Zapbind (using Poisson-Boltzman electrostatics approximation),
together with a semi-empirical method using the LocalSCFv2.0
application (Fujitsu FQS Poland Sp. z o. o., Krakow, Poland) [56].
Virtual hit compounds were acquired from vendors (Table 1) and
were characterised by LC-MS. Two different batches of compound
14 with slightly different appearance and aqueous solubility were
obtained. However, these were indistinguishable by LC-MS and
NMR, and spectral data was in accord with the structure shown.
4.44. Western blotting
SDS-PAGE and electroblotting were carried out as usual. For
Western blotting, the following antibodies were used: rabbit anti-
BCL, Cell Signalling #2872; mouse anti c-Myc (9E10), SantaCruz
#sc-040; rabbit anti-GAPDH, Cell Signalling #2118; rabbit anti-
F. Soukarieh et al. / European Journal of Medicinal Chemistry 124 (2016) 200e217 215eIF4E-BP1, Cell Signalling #9644; rabbit anti-phospho-eIF4E-BP1,
Cell Signalling #9459; rabbit anti-eIF4E, Cell Signalling #9742;
rabbit anti-eIF2A (D7D2) XP, Cell Signalling #5324; mouse anti-
eIF2A, Cell Signalling #2103; rabbit anti-cyclin D1, SantaCruz
#753; mouse anti-b-actin, Sigma #A3854; (primary); anti-mouse-
HRP conjugate, 1:5,000, Dako P0447; anti-rabbit-HRP conjugate,
1:10,000, GE Healthcare NA9340V.
4.45. Recombinant eIF4E
Expression and puriﬁcation of eIF4E followed a modiﬁed pro-
cedure of that already published [15]. Brieﬂy, the procedure was
modiﬁed to allow for rapid, scale-up production of eIF4E and will
be published separately (manuscript in preparation). Following
puriﬁcation, the protein concentration was adjusted to 1 mg mL1
(Vivaspin concentrator, 5 kDa cut-off) and the solution was ﬂash-
frozen in 200-mL aliquots, which were stored at 80 C.
4.46. Fluorescence polarisation assay
A ﬂuorescent probe (EDA-m7GDPeATTO-465; NU-827-465) was
obtained from Jena Biosciences; 96-well black plates (Optiplate®)
were from Perkin Elmer. Recombinant eIF4E and the probe were
diluted (20 mM HEPES, pH 7.4, 100 mM KCl, 1 mM DTT) to obtain
the required concentration. m7GTP (Sigma-Aldrich) and m7GMP
were used as positive controls. The ﬁnal volume in each well was
100 mL. Compound screening was performed using a ﬁnal DMSO
concentration of 1%. Fluorescence polarisation measurements were
recorded on a Perkin-Elmer Envision 2104 plate reader. For Kd
calculation, logarithmic serial dilutions of test compounds were
prepared. Background-corrected readings were plotted against test
compound concentration in GaphPad Prism (Version 5.0) in order
to obtain Kd values.
4.47. Crystallisation of ligand-bound eIF4E
A 3.2-mM solution of 4G-I (eIF4G-derived peptide, KKRY-
DREFLLGFQF) or 4EBP-I (4E-BP-derived peptide, RIIYDRKFLMECRN)
in crystallisation buffer (50 mM Tris, pH 8.0, 150 mM KCl, 1 mM
DTT) was added to an equal volume of a solution of recombinant
human eIF4E (8 mg mL1). A ligand solution (50 or 100 mM) in
DMSO was added to a ﬁnal DMSO concentration of 2.5%. Thin
needle-like crystals grew over a period of 3e7 d by the hanging
drop method (1:1 proteinemother liquor) over 21e31% PEG-8,000,
1e3% (NH4)2SO4, 100 mM HEPES, pH 7.5. Drops containing crystals
were added to 50 mL mother liquor vortex-mixed for 3 min. This
was used as a seed stock (at 1:1 and 1:10 dilution) for seeding back
into the same conditions. Needle-like crystals grew in 1e7 d and
were frozen directly in liquid N2. For back-soaking experiments
with ligand 7a complex crystals, crystals were transferred to a drop
containing a 1:1 ratio of crystallisation buffer and 100 mM HEPES,
pH 7.5, 21% PEG-8,000, supplemented with 7a. The drop was
equilibrated over 100 mM HEPES, pH 7.5, 21% PEG-8000 for 5 min
before ﬂash-freezing the crystals in liquid N3.
X-ray crystallography data collection and structure reﬁnement.
Data were collected at Diamond Light Source, UK, from single
crystals using beamlines I02, I04, and I04-1, at 100 K, and were
processed using either iMOSFLM [57] or XDS [58] using scaling
with SCALA [59]. The structures were solved with the AutoMR
command in the PHENIX suite [60], which uses the programme
PHASER [61]. A single eIF4E and 4E-BP chain from the unit cell of
PDB entry 2V8Y (ligand removed) was used as the search model
and all structures were subjected to several rounds of reﬁnement in
PHENIX and manual reﬁnement in COOT [62], including ligand
ﬁtting and a rebuilding of the 4G-I peptide chain (where necessary).4.48. Rabbit reticulocyte lysate in vitro translation assays
PCR (hot KOD polymerase kit, Novagen®; Qiaquick PCR puriﬁ-
cation kit, QIAGEN) was used to amplify the luciferase DNA
sequence from a pGl3 vector with the primers
GCGGCCGGCCGCCCCGACTCTAGAA and GGGGTAATACGACTCAC
TATAGGGTCC-ACCTCGAATCACTAGTCAGCTG. Alternatively, the
plasmid pRHCVF, which contains Renilla luciferase as the upstream
cistron and ﬁreﬂy luciferase as the downstream cistron preceded by
the HCV IRES, was digested with HpaI and use to prime in vitro
transcription reactions. In vitro RNA synthesis was performed on
the resulting DNA using a mMessage mMachine® T7 kit (Ambion).
The resulting capped RNAs were puriﬁed using microSpin G-50
columns (GE Healthcare), analysed by agarose gel electrophoresis,
and were stored in aliquots at80 C. An in-vitro translation Rabbit
Reticulocyte Lysate System kit (Promega) was used as per the
manufacturer's instructions. Brieﬂy, 20 ng capped RNA was incu-
bated with rabbit reticulocyte lysate in a ﬁnal reaction volume of
20 mL. The mixture was incubated at 30 C for 90 min and then
placed on ice for immediate analysis. Diluent (H2O) was replaced by
test compound solutions in the course of compound screening and
the ﬁnal DMSO concentration was limited to 1%. Assays were per-
formed with m7GTP as a positive control and a DMSO negative
control (which was assigned a 100% value).
4.49. Ultraviolet cross-linking assay
In a way similar to RNA luciferase synthesis, a 392-base coding
region of the pGL3 vector was ampliﬁed and the corresponding
RNA was generated using the T7 RiboMax large-scale production
system (Promega) according to the manufacturer's instructions.
The resulting transcript was then cap-radiolabelled with 32P-[a-
GTP] (speciﬁc activity 400 Ci mmol1, Hartmann Analytic GmbH)
using a vaccinia virus capping system (New England Biolabs) and
puriﬁed using a microSpin G-50 column. A 1-mL aliquot of the
labelled RNA was transferred to a scintillation vial with 2 mL
scintillation liquid (Ecoscint A, National Diagnostics), and was read
in a scintillation counter (Wallac Winspectral 1414 liquid scintil-
lation counter). The disintegration per minute readings were con-
verted to Ci units, and the concentration of radiolabelled capped
RNA was then calculated based the original 32P-GTP stock con-
centration after correction based on decay time. Assay procedures:
to work out suitable concentrations of RNA and eIF4E to be used in
the assay, a titration experiment of eIF4E against a constant con-
centration of labelled RNA was carried out. The assay was per-
formed using 96-well ﬂat-bottom plates (Corning, Costar®), in a
volume of 20 mL for each reaction (in a ratio of 10:5:5 for buffer,
RNA, eIF4E, respectively). Plates were kept on ice and were exposed
to a UV radiation source of 275 J m2 at a distance of 3 cm for a period
of 30 min. The plate wells were then treated with a mixture of
RNase (0.1 mg mL1 RNase A, 0.1 mg mL1 RNase T1, 0.1 mg mL1
RNase V1) at 37 C for 30 min. Samples were then separated by
SDS-PAGE and the gels were dried and exposed to autoradiography
ﬁlm for 24 h, before being read using a Typhoon 9500 FLA scanner.
Band intensities were quantiﬁed using image analysis software
(Image J, Version 1.46) relative to a DMSO controls.
4.50. 35S-methionine incorporation assay
HeLa cells were seeded into 12-well plates at 1  105 cells per
well for 2-h and at 6  104 cells per well for 24-h treatment ex-
periments. Cells were incubated for 24 h until they reached 70%
conﬂuency and were then treated with test compounds. Cells were
methionine-starved for 30 min by changing to a Met-free DMEM
medium, with renewed test compound addition. A 1.5-mL aliquot of
F. Soukarieh et al. / European Journal of Medicinal Chemistry 124 (2016) 200e21721635S-methionine (30 mCi mL1, Hartmann Analytic) was added to
eachwell of the plates, which were incubated for 30min. The plates
were placed on ice and medium was removed. The cells were
washed with warm phosphate-buffered saline (PBS) twice and
lysed by storing at 80 C for 30 min in lysis buffer (Promega). For
quantiﬁcation, protein was precipitated with trichloroacetic acid,
collected, dried, transferred to scintillation liquid, and read in a
scintillation counter.
4.51. Polysome proﬁling assay
HeLa cells were seeded in 15-cm diameter dishes and were left
for 24 h to reach 70% conﬂuency. Cells were treated with test
compound for 2 h and cycloheximide (0.1 mg mL1) was added.
Cells were harvested on ice and then lysed using lysis buffer
300 mM NaCl, 15 mM MgCl2, 15 mM Tris (pH 7.5) containing
1 mg mL1 heparin sulfate and 0.1 mg mL1 cycloheximide, sup-
plemented with 0.1% (v/v) Triton X-100. Cell lysates were loaded on
sucrose gradients (10e60% sucrose in 12-mL Sorvall centrifuge
tubes) made with the same buffer, and were ultracentrifuged using
a SW40Ti (Beckman Coulter) centrifuge at 38,000 r.p.m. for 2 h. The
gradients were then separated into fractions of 1 mL with contin-
uous UV absorbance recording.
Author contributions
The manuscript was written through contributions of all au-
thors. All authors have given approval to the ﬁnal version of the
manuscript.
PDB ID codes
5EI3, 5EIR, 5EKV, 5EHC.
Acknowledgements
The work presented here was funded by the Association for
International Cancer Research (AICR; grant reference 06-063), the
Medical Research Council (MRC), and Cancer Research UK (CRUK;
grant reference C18648/A10174) and was supported by the Well-
come Trust Multi-User Equipment Grants 081287/Z/06/Z and
101527/Z/13/Z. FS was supported by a Scholarship from the Uni-
versity of Damascus, Syria.
References
[1] L.D. Kapp, J.R. Lorsch, The molecular mechanics of eukaryotic translation,
Annu. Rev. Biochem. 73 (2004) 657e704.
[2] N. Sonenberg, A.G. Hinnebusch, Regulation of translation initiation in eu-
karyotes: mechanisms and biological targets, Cell 136 (2009) 731e745.
[3] A.M. Borman, Y.M. Michel, C.E. Malnou, K.M. Kean, Free poly(A) stimulates
capped mRNA translation in vitro through the eIF4G-poly(A)-binding protein
interaction, J. Biol. Chem. 277 (2002) 36818e36824.
[4] T. von der Haar, J.D. Gross, G. Wagner, J.E. McCarthy, The mRNA cap-binding
protein eIF4E in post-transcriptional gene expression, Nat. Struct. Mol. Biol.
11 (2004) 503e511.
[5] B. Ghosh, A.O. Benyumov, P. Ghosh, Y. Jia, S. Avdulov, P.S. Dahlberg,
M. Peterson, K. Smith, V.A. Polunovsky, P.B. Bitterman, C.R. Wagner, Nontoxic
chemical interdiction of the epithelial-to-mesenchymal transition by target-
ing cap-dependent translation, ACS Chem. Biol. 4 (2009) 367e377.
[6] A.C. Gingras, B. Raught, N. Sonenberg, eIF4 initiation factors: effectors of
mRNA recruitment to ribosomes and regulators of translation, Annu. Rev.
Biochem. 68 (1999) 913e963.
[7] I.G. Goodfellow, L.O. Roberts, Eukaryotic initiation factor 4E, Int. J. Biochem.
Cell. Biol. 40 (2008) 2675e2680.
[8] A. De Benedetti, J.R. Graff, eIF-4E expression and its role in malignancies and
metastases, Oncogene 23 (2004) 3189e3199.
[9] J.R. Graff, S.G. Zimmer, Translational control and metastatic progression:
enhanced activity of the mRNA cap-binding protein eIF-4E selectively en-
hances translation of metastasis-related mRNAs, Clin. Exp. Metastasis 20(2003) 265e273.
[10] S.G. Zimmer, A. DeBenedetti, J.R. Graff, Translational control of malignancy:
the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor for-
mation, growth, invasion and metastasis, Anticancer Res. 20 (2000)
1343e1351.
[11] K. Feoktistova, E. Tuvshintogs, A. Do, C.S. Fraser, Human eIF4E promotes
mRNA restructuring by stimulating eIF4A helicase activity, Proc. Natl. Acad.
Sci. U. S. A. 110 (2013) 13339e13344.
[12] Y. Jia, V. Polunovsky, P.B. Bitterman, C.R. Wagner, Cap-dependent translation
initiation factor eIF4E: an emerging anticancer drug target, Med. Res. Rev. 32
(2012) 786e814.
[13] J.R. Graff, B.W. Konicek, T.M. Vincent, R.L. Lynch, D. Monteith, S.N. Weir,
P. Schwier, A. Capen, R.L. Goode, M.S. Dowless, Y. Chen, H. Zhang, S. Sissons,
K. Cox, A.M. McNulty, S.H. Parsons, T. Wang, L. Sams, S. Geeganage,
L.E. Douglass, B.L. Neubauer, N.M. Dean, K. Blanchard, J. Shou, L.F. Stancato,
J.H. Carter, E.G. Marcusson, Therapeutic suppression of translation initiation
factor eIF4E expression reduces tumor growth without toxicity, J. Clin. Invest.
117 (2007) 2638e2648.
[14] E. Darzynkiewicz, J. Stepinski, I. Ekiel, C. Goyer, N. Sonenberg, A. Temeriusz,
Y. Jin, T. Sijuwade, D. Haber, S.M. Tahara, Inhibition of eukaryotic translation
by nucleoside 50-monophosphate analogs of mRNA 50-cap: changes in N7
substituent affect analog activity, Biochemistry 28 (1989) 4771e4778.
[15] C.J. Brown, I. McNae, P.M. Fischer, M.D. Walkinshaw, Crystallographic and
mass spectrometric characterisation of eIF4E with N7-alkylated cap de-
rivatives, J. Mol. Biol. 372 (2007) 7e15.
[16] Y. Jia, T.L. Chiu, E.A. Amin, V. Polunovsky, P.B. Bitterman, C.R. Wagner, Design,
synthesis and evaluation of analogs of initiation factor 4E (eIF4E) cap-binding
antagonist Bn-7-GMP, Eur. J. Med. Chem. 45 (2010) 1304e1313.
[17] P. Ghosh, C. Park, M.S. Peterson, P.B. Bitterman, V.A. Polunovsky, C.R. Wagner,
Synthesis and evaluation of potential inhibitors of eIF4E cap binding to 7-
methyl GTP, Bioorg. Med. Chem. Lett. 15 (2005) 2177e2180.
[18] E. Darzynkiewicz, I. Ekiel, P. Lassota, Tahara. Inhibition of eukaryotic trans-
lation by analogs of messenger RNA 50-cap: chemical and biological conse-
quences of 50-phosphate modiﬁcations of 7-methylguanosine 50-
monophosphate, Biochemistry 26 (1987) 4372e4380.
[19] J. Kowalska, M. Lukaszewicz, J. Zuberek, M. Ziemniak, E. Darzynkiewicz,
J. Jemielity, Phosphorothioate analogs of m7GTP are enzymatically stable in-
hibitors of cap-dependent translation, Bioorg. Med. Chem. Lett. 19 (2009)
1921e1925.
[20] X. Chen, D.J. Kopecky, J. Mihalic, S. Jeffries, X. Min, J. Heath, J. Deignan, S. Lai,
Z. Fu, C. Guimaraes, S. Shen, S. Li, S. Johnstone, S. Thibault, H. Xu, M. Cardozo,
W. Shen, N. Walker, F. Kayser, Z. Wang, Structure-guided design, synthesis,
and evaluation of guanine-derived inhibitors of the eIF4E mRNA-cap inter-
action, J. Med. Chem. 55 (2012) 3837e3851.
[21] S. Li, Y. Jia, B. Jacobson, J. McCauley, R. Kratzke, P.B. Bitterman, C.R. Wagner,
Treatment of breast and lung cancer cells with a N-7 benzyl guanosine
monophosphate tryptamine phosphoramidate pronucleotide (4Ei-1) results
in chemosensitization to gemcitabine and induced elF4E proteasomal degra-
dation, Mol. Pharm. 10 (2013) 523e531.
[22] E. Papadopoulos, S. Jenni, E. Kabha, K.J. Takrouri, T. Yi, N. Salvi, R.E. Luna,
E. Gavathiotis, P. Mahalingam, H. Arthanari, R. Rodriguez-Mias, R. Yeﬁdoff-
Freedman, B.H. Aktas, M. Chorev, J.A. Halperin, G. Wagner, Structure of the
eukaryotic translation initiation factor eIF4E in complex with 4EGI-1 reveals
an allosteric mechanism for dissociating eIF4G, Proc. Natl. Acad. Sci. U. S. A.
111 (2014) E3187eE3195.
[23] D. Lama, S.T. Quah, C.S. Verma, R. Lakshminarayanan, R.W. Beuerman,
D.P. Lane, C.J. Brown, Rational optimization of conformational effects induced
by hydrocarbon staples in peptides and their binding interfaces, Sci. Rep. 3
(2013) 3451.
[24] C.J. Brown, S.G. Dastidar, H.Y. See, D.W. Coomber, M. Ortiz-Lombardia,
C. Verma, D.P. Lane, Rational design and biophysical characterization of
thioredoxin-based aptamers: insights into peptide grafting, J. Mol. Biol. 395
(2010) 871e883.
[25] P.M. Fischer, Cap in hand: targeting eIF4E, Cell Cycle 8 (2009) 2535e2541.
[26] P.L. Beaulieu, D.R. Cameron, J.M. Ferland, J. Gauthier, E. Ghiro, J. Gillard,
V. Gorys, M. Poirier, J. Rancourt, D. Wernic, M. Llinas-Brunet, R. Betageri,
M. Cardozo, E.R. Hickey, R. Ingraham, S. Jakes, A. Kabcenell, T. Kirrane, S. Lukas,
U. Patel, J. Proudfoot, R. Sharma, L. Tong, N. Moss, Ligands for the tyrosine
kinase p56lck SH2 domain: discovery of potent dipeptide derivatives with
monocharged, nonhydrolyzable phosphate replacements, J. Med. Chem. 42
(1999) 1757e1766.
[27] E. Darzynkiewicz, J. Stepinski, I. Ekiel, C. Goyer, N. Sonenberg, A. Temeriusz,
Y. Jin, T. Sijuwade, D. Haber, S.M. Tahara, Inhibition of eukaryotic translation
by nucleoside 50-monophosphate analogues of mRNA 50-cap: changes in N7
substituent affect analogue activity, Biochemistry 28 (1989) 4771e4778.
[28] Y. Jia, T.L. Chiu, E.A. Amin, V. Polunovsky, P.B. Bitterman, C.R. Wagner, Design,
synthesis and evaluation of analogs of initiation factor 4E (eIF4E) cap-binding
antagonist Bn7-GMP, Eur. J. Med. Chem. 45 (2010) 1304e1313.
[29] K. Seio, T. Miyashita, K. Sato, M. Sekine, Synthesis and properties of new
nucleotide analogues possessing squaramide moieties as new phosphate
isosters, Eur. J. Org. Chem. (2005) 5163e5170.
[30] K. Sato, K. Seio, M. Sekine, Squaryl group as a new mimic of phosphate group
in modiﬁed oligodeoxynucleotides: synthesis and properties of new oligo-
deoxynucleotide analogues containing an internucleotidic squaryldiamide
linkage, J. Am. Chem. Soc. 124 (2002) 12715e12724.
F. Soukarieh et al. / European Journal of Medicinal Chemistry 124 (2016) 200e217 217[31] P. Huang, J. Ramphal, J. Wei, C. Liang, B. Jallal, G. McMahon, C. Tang, Structure-
based design and discovery of novel inhibitors of protein tyrosine phospha-
tases, Bioorg. Med. Chem. 11 (2003) 1835e1849.
[32] C. Zingle, L. Kuntz, D. Tritsch, C. Grosdemange-Billiard, M. Rohmer, Isoprenoid
biosynthesis via the methylerythritol phosphate pathway: structural varia-
tions around phosphonate anchor and spacer of fosmidomycin, a potent in-
hibitor of deoxyxylulose phosphate reductoisomerase, J. Org. Chem. 75 (2010)
3203e3207.
[33] R.J. Herr, 5-Substituted-1H-tetrazoles as carboxylic acid isosteres: medicinal
chemistry and synthetic methods, Bioorg. Med. Chem. 10 (2002) 3379e3393.
[34] M. Sekine, Y. Seio, T. Miyashita, K. Sato, Preparation of Nucleoside Analogs
Having Squaric Acid or Deltic Acid-derived Moiety, Jpn. Kokai Tokkyo Koho
JP2005162631, Japan Science and Technology Agency, Japan, 2005.
[35] B.L. Zhang, Z.Y. Cui, L.L. Sun, Synthesis of 5 0-deoxy-5 '-thioguanosine-50-
monophosphorothioate and its incorporation into RNA 5 '-termini, Org. Lett. 3
(2001) 275e278.
[36] G.H. McGall, A.D. Barone, M. Diggelmann, S.P.A. Fodor, E. Gentalen, N. Ngo, The
efﬁciency of light-directed synthesis of DNA arrays on glass substrates, J. Am.
Chem. Soc. 119 (1997) 5081e5090.
[37] D.K. Dean, An improved synthesis of 50-amino-50-deoxyguanosine, Synth.
Commun. 32 (2002) 1517e1521.
[38] J.M. Delﬁno, C.J. Stankovic, S.L. Schreiber, F.M. Richards, Synthesis of a bipolar
phosphatidylethanolamine: a model compound for a membrane-spanning
probe, Tetrahedron Lett. 28 (1987) 2323e2326.
[39] T. Moriguchi, N. Asai, K. Okada, K. Seio, T. Sasaki, M. Sekine, First synthesis and
anticancer activity of phosmidosine and its related compounds, J. Org. Chem.
67 (2002) 3290e3300.
[40] J.J. Irwin, T. Sterling, M.M. Mysinger, E.S. Bolstad, R.G. Coleman, ZINC: a free
tool to discover chemistry for biology, J. Chem. Inf. Model. 52 (2012)
1757e1768.
[41] M. McGann, FRED pose prediction and virtual screening accuracy, J. Chem. Inf.
Model. 51 (2011) 578e596.
[42] M. McGann, FRED and HYBRID docking performance on standardized data-
sets, J. Comp. Aided Mol. Des. 26 (2012) 897e906.
[43] D.A. Dougherty, Cation-m interactions in chemistry and biology: a new view
of benzene, Phe, Tyr, and Trp, Science 271 (1996) 163e168.
[44] J.C. Ma, D.A. Dougherty, The cation-pi interaction, Chem. Rev. 97 (1997)
1303e1324.
[45] G. Patwardhan, F. Meullenet, M.W. Nowicki, N.J. Oldham, A.E. Willis,
M.D. Walkinshaw, P.M. Fischer, Molecular modeling leading the way: toward
nonnucleotide analogs targeting the eIF4E-mRNA cap interaction as novel
anticancer agents, in: The 238th ACS National Meeting, Washington, DC, USA,
2009 p Abs. MEDI 461.
[46] D.F. Veber, S.R. Johnson, H.-Y. Cheng, B.R. Smith, K.W. Ward, K.D. Kopple,
Molecular properties that inﬂuence the oral bioavailability of drug candidates,
J. Med. Chem. 45 (2002) 2615e2623.
[47] T.I. Oprea, A.M. Davis, S.J. Teague, P.D. Leeson, Is there a difference betweenleads and drugs? A historical perspective, J. Chem. Inf. Comp. Sci. 41 (2001)
1308e1315.
[48] L. Lindqvist, H. Imataka, J. Pelletier, Cap-dependent eukaryotic initiation
factor-mRNA interactions probed by cross-linking, RNA 14 (2008) 960e969.
[49] H.R. Pelham, R.J. Jackson, An efﬁcient mRNA-dependent translation system
from reticulocyte lysates, Eur. J. Biochem. 67 (1976) 247e256.
[50] J. Chan, S.N. Khan, I. Harvey, W. Merrick, J. Pelletier, Eukaryotic protein syn-
thesis inhibitors identiﬁed by comparison of cytotoxicity proﬁles, RNA 10
(2004) 528e543.
[51] S.L. He, R. Green, Polysome analysis of mammalian cells, Methods Enzymol.
530 (2013) 183e192.
[52] J. Marcotrigiano, A.-C. Gingras, N. Sonenberg, S.K. Burley, Cocrystal structure
of the messenger RNA 50 cap-binding protein (eIF4E) bound to 7-methyl-GDP,
Cell 89 (1997) 951e961.
[53] K. Schmitz, F. Hahn, U. Schepers, Modiﬁed GSMP synthesis greatly improves
the disulﬁde crosslink of T7 run-off siRNAs with cell penetrating peptides,
Synlett (2010) 2959e2963.
[54] P.C.D. Hawkins, A.G. Skillman, G.L. Warren, B.A. Ellingson, M.T. Stahl,
Conformer generation with OMEGA: algorithm and validation using high
quality structures from the protein databank and cambridge structural data-
base, J. Chem. Inf. Model. 50 (2010) 572e584.
[55] P.C.D. Hawkins, A. Nicholls, Conformer generation with OMEGA: learning
from the data set and the analysis of failures, J. Chem. Inf. Model. 52 (2012)
2919e2936.
[56] N.A. Anikin, V.M. Anisimov, V.L. Bugaenko, V.V. Bobrikov, A.M. Andreyev,
LocalSCF method for semiempirical quantum-chemical calculation of ultra-
large biomolecules, J. Chem. Phys. 121 (2004) 1266e1270.
[57] T.G.G. Battye, L. Kontogiannis, O. Johnson, H.R. Powell, A.G.W. Leslie,
iMOSFLM: a new graphical interface for diffraction-image processing with
MOSFLM, Acta Crystallogr. D. 67 (2011) 271e281.
[58] W. Kabsch, XDS, Acta Crystallogr. D. 66 (2010) 125e132.
[59] M.D. Winn, C.C. Ballard, K.D. Cowtan, E.J. Dodson, P. Emsley, P.R. Evans,
R.M. Keegan, E.B. Krissinel, A.G.W. Leslie, A. McCoy, S.J. McNicholas,
G.N. Murshudov, N.S. Pannu, E.A. Potterton, H.R. Powell, R.J. Read, A. Vagin,
K.S. Wilson, Overview of the CCP4 suite and current developments, Acta
Crystallogr. D. 67 (2011) 235e242.
[60] P.D. Adams, P.V. Afonine, G. Bunkoczi, V.B. Chen, I.W. Davis, N. Echols,
J.J. Headd, L.-W. Hung, G.J. Kapral, R.W. Grosse-Kunstleve, A.J. McCoy,
N.W. Moriarty, R. Oeffner, R.J. Read, D.C. Richardson, J.S. Richardson,
T.C. Terwilliger, P.H. Zwart, PHENIX: a comprehensive Python-based system
for macromolecular structure solution, Acta Crystallogr. D. 66 (2010)
213e221.
[61] A.J. McCoy, R.W. Grosse-Kunstleve, P.D. Adams, M.D. Winn, L.C. Storoni,
R.J. Read, Phaser crystallographic software, J. Appl. Crystallogr. 40 (2007)
658e674.
[62] P. Emsley, B. Lohkamp, W.G. Scott, K. Cowtan, Features and development of
coot, Acta Crystallogr. D. 66 (2010) 486e501.
